

Review

Excipients in the Paediatric Population: A Review

Khadija Rouaz¹, Blanca Chiclana-Rodríguez^{1,*}, Anna Nardi-Ricart¹, Marc Suñé-Pou^{1,2},
Dèbora Mercadé-Frutos¹, Josep María Suñé-Negre^{1,2}, Pilar Pérez-Lozano^{1,2,†} and
Encarna García-Montoya^{1,2,†}

- ¹ Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; khadirouaz@gmail.com (K.R.); annanardi@ub.edu (A.N.-R.); msunepou@gmail.com (M.S.-P.); debora.mercade@ub.edu (D.M.-F.); jmsune@ub.edu (J.M.S.-N.); perezlo@ub.edu (P.P.-L.); encarnagarcia@ub.edu (E.G.-M.)
- ² Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran via de l'Hospitalet, 199-203, 08090 Barcelona, Spain
- * Correspondence: blchiclr8@alumnes.ub.edu; Tel.: +34-638-53-53-42
- † These authors contribute equally to this paper.

Abstract: This theoretical study seeks to critically review the use of excipients in the paediatric population. This study is based on the rules and recommendations of European and American drug regulatory agencies. On the one hand, this review describes the most frequent excipients used in paediatric medicine formulations, identifying the compounds that scientific literature has marked as potentially harmful regarding the side effects generated after exposure. On the other hand, this review also highlights the importance of carrying out safety -checks on the excipients, which, in most cases, are linked to toxicity studies. An excipient in the compilation of paediatric population databases is expected to target safety and toxicity, as in the STEP database. Finally, a promising pharmaceutical form for child population, ODT (Orally Disintegrating Tablets), will be studied.

Keywords: excipients; paediatrics; security; toxicology; STEP and ODT



Citation: Rouaz, K.; Chiclana-Rodríguez, B.; Nardi-Ricart, A.; Suñé-Pou, M.; Mercadé-Frutos, D.; Suñé-Negre, J.M.; Pérez-Lozano, P.; García-Montoya, E. Excipients in the Paediatric Population: A Review. *Pharmaceutics* **2021**, *13*, 387. <https://doi.org/10.3390/pharmaceutics13030387>

Academic Editor: José B. Fariña

Received: 18 February 2021

Accepted: 10 March 2021

Published: 13 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The scientific literature suggests that most commercialized drugs are not suitable to be used on the paediatric population, as they are presented in an inappropriate pharmaceutical dosage or form, or because of the excipients they contain. In the face of this reality, compounding is the alternative for paediatric patients. Auxiliary substances or excipients should be used in the development of a compounding formula in order to allow the drug to be administered in an easily and personalized manner. By doing so, the active ingredient will be formulated in a stable, effective, and safe form [1].

The process of formulating excipients in paediatrics is a complicated task that requires various considerations to be accounted for in order to for them to be appropriate; variables such as an acceptable taste, age, dosage forms, among others, must be taken into account when selecting safe excipients. Furthermore, children's rapid growth and development are associated with changes in various organs, body composition, protein bonds, active transport mechanisms and metabolic pathways, which must also be taken into account [2]. In addition to being a complicated task, it is also a critical step in the development of paediatric formulations, as some acceptable excipients in formulations for adult patients are not suitable for paediatric use.

It is thus of particular relevance to carry out an assessment of the safety of excipients prior to their use in paediatrics. Indeed, Georg Schmitt [3] advocates for non-clinical safety studies being carried out in juvenile animals to assess excipient toxicity or sensibility and also to establish safe exposures in paediatric age groups. He specifically recommends that excipient toxicity studies also be carried out, as they provide a detailed assessment

of clinical risk. He further suggests that even excipients with significant toxic potential for children may be acceptable after a rigorous assessment of the risk they pose is made. Another factor to be considered for toxicological studies is the extent to which the target disease may be alleviated by the formulation of that medicine. Thus, pharmaceutical companies should filter the demands for safety assessments by selecting those that will contribute to a potential therapeutic benefit, while helping to develop a reference list of excipients generally considered safe for use in paediatric formulations. In this way, the clinical decision-making process will be made easier.

This theoretical study's main objective is to critically review the use of excipients in paediatrics with an emphasis on the issue of safety, mainly on the basis of toxicological studies. This will enable information to be obtained that will allow decisions to be made regarding the masterful preparation of formulations. This study also seeks to investigate the development of databases and initiatives in order to record corroborated information on excipients for paediatric use, thus serving as a guide for clinical professionals.

To do this, databases such as Web of Science, PubMed, SciFinder and SciFindern Search, as well as books related to the subject, were consulted. Please note that most of the selected literature is from the last two decades. Subsequently, six tables were created to provide details on the data obtained:

- Table 1. Toxicity database.
- Table A1. Most important characteristics of the excipients discussed in this review (in alphabetical order).
- Table A2. Examples of solid and semi-solid medicines used in Spain for the paediatric population: List of excipients and relevant characteristics of the pharmaceutical form (PF) (performed consultation of CIMA database, September 2020).
- Table A3. Examples of liquid medicines used in paediatrics: List of excipients and relevant characteristics of (PF).
- Table A4. Examples of FDA-registered drugs used in paediatrics (FDA database and DAILYMED October 2020).
- Table A5. Examples of liquid formulations for paediatric use in research articles.

Table 1. Toxicity databases and public resources.

| Name | Website | Creator |
|--|---|--|
| ACToR—Aggregated Computational Toxicology Resource | www.actor.epa.gov/actor/home.xhtml (accessed on 15 November 2020) | US Environmental Protection Agency's (EPA) National Center for Computational Toxicology (NCCT) |
| STEP—Safety and Toxicity of Excipients for Paediatrics * | www.eupfi.org/step-database-info/ (accessed on 15 November 2020) | European Paediatric Formulation Initiative |
| TOXNET—Toxicology Data Network | www.nlm.nih.gov/toxnet/index.html (accessed on 15 November 2020) | Specialized Information Services (SIS) USA |
| Vitic | www.lhasalimited.org/products/vitic.htm (accessed on 2 November 2020) | Lhasa Limited |

* The purposes of the STEP database can be consulted in the Appendix A.

2. Paediatric Regulatory Context

Changes in physical, metabolic and psychological processes that occur during children's growth, from birth to adulthood, suggest that children should not be considered as young adults, and nor should they be grouped as a single group. Rather, the pharmaceutical development of paediatric drugs should focus on several acceptable dosage forms that are able to meet the needs of most children in different age groups. This can be achieved by developing dosage forms which facilitate the administration of a dose range which would vary according to the child's age and/or other important parameters [4].

Before there were regulations for the development of paediatric drugs, children were known as “therapeutic orphans”. They lost the advances of conventional medicine, since the vast majority of advances were aimed at the adult population, and there were not many approved medicines for children. Children were treated with approved drugs following successful studies on adults, but with few or no trials on the paediatric population (off-label use). The large number of subsequent issues with clinical trials on children, as well as the need for drug authorization in the paediatric population, among other reasons, were the driving factors for the creation of a legislative and regulatory framework for clinical studies in paediatrics. The US pioneered these in the late 1980s, and with the adoption of these paediatric regulatory initiatives, significant improvements were made [4].

It was only in 1997 that European regulators agreed to strengthen legislation on the use of new medicines in children. In 2000, European health ministers asked the European Commission to make proposals for a legislation to ensure that new paediatric medicines placed on the market were tailored to the specific needs of children. In 2004, after a major debate, a regulatory bill was issued, which took into account lessons learned from paediatric regulation that the US was already addressing [5]. On 26 January 2007, the Paediatric Regulation entered into force in the European Union, and focused mainly on regulating the development of paediatric formulations for children between 0 and 18 years of age, but also sought to:

- Ensure that these medicines were of good quality.
- Verify that paediatric medicines were produced following ethical and legitimate research, that children were not subjected to unnecessary trials.
- Improve the accessibility and availability of information on drug use in the paediatric population.
- Such regulations led to the establishment of the Paediatric Committee (PDCO), whose main function was to regulate the studies that companies should conduct in children as part of a Paediatric Research Plan (PRP) [6].
- The Paediatric Regulation consists of [7]:
- Regulation (EC) 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use; and
- Regulation (EC) 1902/2006, an amending regulation in which changes were made to the original text in relation to the European Commission’s decision-making procedures.

In October 2017, the European Commission published a ten-year report on the implementation of the Paediatric Regulation. The report showed an increase in medicines for children in most therapeutic areas over the past ten years, especially in rheumatology and infectious diseases. However, in rare diseases, progression was lower. A report on the first five years was also published in June 2013, which concluded that paediatric development had become a more integral part of the overall development of medicines in the European Union [4,8].

The European Guideline on pharmaceutical development of medicines for paediatric used [4] offers several tips for paediatric drug formulation.

Excipients in a paediatric formulation should be chosen appropriately, avoiding any excipients that are potentially toxic or unsuitable for children. Choosing the right excipients in the development of a new paediatric drug is one of the most important aspects, as it requires special safety considerations. In general, the following aspects should be taken into account when selecting an appropriate excipient for a paediatric medicinal product [4]:

- Excipient function in formulation and possible alternatives.
- Safety profile of the excipient for children in target age groups, based on a unique and daily exposure.
- Expected duration of treatment: short term (a single dose for a few days) or long term (weeks and/or months).
- Severity of the condition to be treated and therapeutic alternatives.
- Patient acceptability, including palatability.

- Allergies and sensitization. Children suffer from sensitization problems more commonly than adults. Applicants should avoid, when possible, excipients with known potential to cause sensitization or allergies.

If the use of any excipient in the formulation that produces or may pose any risk to the child cannot be avoided, the added value of the chosen pharmaceutical form of dosing (and the route of administration) should be balanced with the possible use of another. However, security issues can only become apparent when the product is used on a larger scale.

Furthermore, the first joint paediatric regulatory action was taken by the ICH (The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), an organization working on harmonizing drug regulation requirements between the EU, Japan and the US. In July 2000 Guideline E11 (R1) was published: Clinical investigation of medicinal products in the paediatric population, with the final version in August 2017 [9].

The objectives of this guide were to encourage and facilitate the development of paediatric medicines at the international level, as well as to provide a summary of critical problems in the development of these medicines and new approaches to their safe, efficient and ethical clinical study. ICH E11 became an important tool in the design of paediatric clinical research worldwide, providing guidelines (rather than proscribing practice) [9,10].

The WHO launched the initiative Making Medicines Child Size in 2008 to issue a list of essential medicines for children, betting on quality paediatric development and adequate access of these medicines to the entire paediatric population, in particular underdeveloped countries [11]. The most current one is the 7th edition, which was published in 2019 (WHO model list of essential medicines for children) [12].

In the early 1980s, the FDA (Food and Drug Administration) began taking steps to provide incentives to the pharmaceutical industry for the development of paediatric drugs. In 1994, the Paediatric Labelling Rule was issued, requiring the authorization of a new paediatric drug to be supported by safety and efficacy data to support its use. However, that rule was not mandatory and was unsuccessful. For this reason, the US-FDA proposed in 1998 Paediatric rule which proposed to guarantee the above-mentioned objectives, both at and after the approval of the new drug [13].

It should also be noted that the FDA (Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients) published a document that provides guidance on the development of safety profiles to support the use of new excipients as components of drugs or biological products, which could be applied in paediatric experiments [14,15].

Examples of Databases and Initiatives for the Registration of Information on Excipients Used in the Paediatric Population

It is certainly necessary to take into account the safety of excipients used in paediatric products, as the toxicity of these excipients may differ from that of adults [16]. Under this assumption, it is essential to develop methodologies that provide an integrated assessment of exposure to potentially toxic excipients contained in medicines. Therefore, in 2007, members of pharmaceutical industries, hospitals and academics interested in improving drug formulations in paediatrics founded the European Paediatric Formulation Initiative (EUPFI). The latter sought to address safety problems linked to excipients used in children [17], as well as the development of platforms for the systematic evaluation of excipients in new-borns [18].

EUPFI is currently a consortium of 10 pharmaceutical companies, 5 universities, 1 hospital and, exclusively, the European Medicines Agency (EMA) as an observer. The goals and objectives of this consortium are summarized in [19]:

1. Identify the problems and challenges associated with the development of paediatric formulation and consider ways to obtain better medicines and dosage forms clinically relevant to children.
2. Promote early pharmaceutical consideration for the development of paediatric medicines.

3. Identify potential information and knowledge gaps in the development of paediatric formulations.
4. Improve the availability of information from paediatric formulations.

The scientific literature shows that excipients commonly used in adult medicines have been associated with high toxicological risks and safety problems in children [20]. Following the United States Paediatric Formulation Initiative (USPFI) and Global Paediatric Research (GRIP), the Paediatric Excipient Safety and Toxicity Database (STEP) was created to address the need for effortless access to information about the excipients' safety and toxicity [21]. The STEP database is presented as a resource of information to facilitate access to data on the use and acceptability of excipients in children, thus allowing a rapid evaluation of the risks due to the use of certain excipients in the paediatric population and an improvement in the scientific decision making [2,22]. Furthermore, the STEP database provides comprehensive and comparative information on the safe use and acceptability of excipients in paediatrics. For the reasons listed above, the STEP database stands out with respect to other existing public resources (such as TOXNET) or databases (such as Vitic or ACToR) that organize their informational content in free text format, thus preventing data from being filtered as needed (see Table 1) [23].

In general, the above purposes go in line with increasing the number of excipients registered in the database to be useful in practical research. Therefore, the following selection criteria were considered for excipients of interest [2]:

1. Excipients known to be toxic/have general safety issues.
2. Frequency of appearance as contaminants or toxics in paediatrics (where applicable).
3. Evidence in the toxicity literature in paediatrics. The above criteria were applied to identify excipients for inclusion in the STEP database. Excipients were short-listed/prioritized through surveys within EU and US PFI members.

According to the above criteria, in the development of databases on the safety and toxicity of excipients in the paediatric population, the following are prioritized, as they are most likely to cause damage and side effects in this population [2]:

1. Propylene glycol (PG)
2. Ethanol
3. Polysorbate 80
4. Benzyl alcohol
5. Parabens (propyl, methyl, ethyl and butyl)
6. Benzalkonium chloride
7. Aspartame
8. Sorbitol
9. Benzoic acid
10. Sodium benzoate

In 2014, the first version of the STEP database was launched for the systematic evaluation of its integrity, quality, configurability, usability, and maintainability under the daily practices of the different and diverse professionals who use it. After launch, a validation study of the tool was initiated with the following objectives [2]:

1. Validate the STEP Version 1 database against the potential needs of end users to ensure that the STEP database meets users' expectations.
2. Evaluate the functionality and usability of data application by
 - a. Ensuring proper ease of use (navigation), understanding and user satisfaction.
 - b. Characterizing how easy it is to perform a task using the database.
 - c. Identifying problems in interaction with systems.
3. Evaluate the impact of this database on the development of paediatric medicines.
4. Establish viable recommendations to further improve the functionality of the system and increase its beneficial effects on the development of paediatric medicines.

The results of the validation study identified different database usage issues, which are grouped into three areas: I. Content and presentation of results; II. Adequacy of the database to the characteristics of different users, navigation features; and III. Search. Many of the problems observed might have happened due to assuming that users would have sufficient knowledge, therefore some elements were not clearly exposed for the new user to understand. Furthermore, users with limited computer skills may also find the registration process confusing. These issues involved changes and improvements to STEP design and functionality, making it a more efficient database when deriving from a Version 2 [21].

To perform an adequate risk/benefit assessment of the current medication standard, it is necessary to compare the daily amount of excipients in the most vulnerable patient with clinically established safety levels for the same age group. The SEEN project is an example of this, as it developed a retrospective cohort study, with neonatal patients (age 5 or younger) treated with multiple medicines. Preparations were recorded with ethanol, propylene glycol, benzyl alcohol, parabens, aspartame, glycerol, sorbitol and polysorbate-80 and cumulative amounts [24] were calculated.

The results obtained demonstrated limited knowledge about the acceptability of different dosage forms, flavours and, more importantly, the safety of formulation excipients in relation to the age and stage of development of children [24].

3. Excipients: Functions and Main Adverse Effects

Paediatric formulations need excipients to maintain their quality and promote the acceptability of childhood patients [25]. However, just because they are necessary does not mean that they are toxicity-free products; in fact, a study by Georgi and collaborators [26,27] confirms that many of the medicines used in paediatrics contain some toxic or potentially toxic excipient for the paediatric population, with this data being present in two-thirds of new-borns in 21 European countries. Thus, excipients used in paediatric formulations require a thorough assessment of short-term and long-term safety prior to their use in these formulations [28]. A classification of the main excipients will then be developed according to the role they play in the formulation, mentioning the possible adverse effects on the paediatric population. Furthermore, a summary appendix (Appendix B (Table A1)) of the excipients discussed in this paper will be prepared.

3.1. Diluents

Lactose, starch and microcrystalline cellulose are often used as diluents, as they are generally safe in the adult population.

3.1.1. Lactose

Lactose, which is a mandatory excipient, is recommended not to be used in patients with lactose intolerance and is contraindicated in patients with galactosemia [1]. It may cause hypersensitivity reactions in children and new-borns. Infants with lactose intolerance do not properly metabolize lactose, due to the deficiency of the enzyme lactase, thus causing the accumulation of lactic acid, hydrogen and carbon dioxide. Symptoms such as severe abdominal pain, flatulence, bloating or swelling and diarrhoea may, therefore, appear, as well as systemic symptoms such as muscle, joint pain and eczema [28]. It should be noted that children may sometimes have very severe and prolonged reactions to lactose that can lead to additional complications, such as dehydration, bacterial proliferation and metabolic acidosis [1,28].

Starch, dehydrated calcium hydrogen phosphate, erythritol and cellulose powder are alternatives to lactose in paediatric formulations. They have lactose-like flow properties and produce tablets that can disaggregate in a time less than lactose [28].

3.1.2. Starch

Starch is one of the most commonly used excipients and, in addition to being a diluent, it has binder and disintegrating properties. Due to its properties, starch should be preserved

in a dry environment, as it can be an excellent growing medium for microorganisms in case of moisture, which may cause microbiological contaminations. In addition, it may give proliferation of carcinogenic aflatoxins, if contaminated by two species of fungi closely enhanced by each other: *Aspergillus flavus* and *Aspergillus parasiticus* [29].

3.1.3. Microcrystalline Cellulose

Microcrystalline cellulose is a partially depolymerized purified cellulose that is presented as a white, odourless and tasteless crystalline powder composed of porous particles. It is commercially available in different particle sizes and moisture grades that have different properties and applications. It is considered a relatively non-toxic and non-irritating material. It is not absorbed systemically after oral administration and therefore has little toxic potential [29,30].

Microcrystalline cellulose is used in pharmaceutical products, mainly as a binder and thinner in tablet and oral capsule formulations. In addition to its use as a binder and thinner, it also has some lubricating and disintegrating properties that make it useful for forming tablets [30].

3.2. Solvents

Some of the most common solvents are water, ethyl alcohol, propylene glycol (PG), glycerol and polyethylene glycol [28,29].

3.2.1. Water

Water is the most commonly used agent in paediatric formulations, as liquid preparations are easier to administrate and allow a more accurate dose adjustment [1,29]. Water is an ideal medium for the proliferation of microorganisms (bacteria and fungi) despite their purification, which is why antimicrobial agents have to be added.

In paediatric oral formulations, the total volume of fluid is of vital importance for the taste and ability to adequately measure the volume to be administered: in children under 5 years of age a volume of less than 5 mL should be administered and, in children under 10 years of age, a volume of less than 10 mL [29] should be administered.

3.2.2. Ethyl Alcohol (Ethanol)

Ethanol is one of the excipients of concern to international health regulatory agencies, as it causes neurotoxicity and cardiovascular problems in the paediatric population; it is a potentially harmful excipient in neonates. For this reason, permissible maximum limits have been set and, in some countries, non-alcoholic medicines are to be established. It is a very permeable excipient with regard to the blood–brain barrier, and the one most commonly used in oral medicinal products, reaching 63% of cases [26]. It is rapidly absorbed into the gastrointestinal tract and is primarily metabolized in the liver to acetaldehyde, which is oxidized to acetate [29].

Indeed, Macrel and Bernando's review of liquid formulations in Brazil has furthered our understanding of the high use of ethanol. These researchers demonstrated that ethanol is used in various concentrations and functions: as solvent (main function), co-saver, flavouring agent, preservative and as an extraction solvent in herbal medicines [26,27]. It also has antimicrobial properties and increases the permeability of many preparations [29].

The use of ethanol as an excipient carries potential hazards and adverse effects, which are already observed at a dose of 100 mg/dL. These effects include hypoglycaemia, acidosis and hydro-electrolytic alterations. Very high intake can lead to stupor, coma, respiratory depression and cardiovascular collapse. Hypoglycaemic seizures may also occur in children [29,31]. For all these side effects, any alcohol should be avoided in paediatric forms. However, it is still used in many liquid preparations, because it is the only solvent that allows the solubilization of certain active substances [29].

In both the United States and the European Union, guidance on maximum ethanol limits in medicinal formulations is increasing [17]. According to the World Health Orga-

nization and a regulation existing in the United States, the maximum alcohol content in paediatric formulations should not exceed the limits specified in Table A1 [29,31,32].

It should be noted that ethanol was also able to interact with many active substances of other medicines that the child is taking [29] and, therefore, possible interactions must be studied prior to concomitant administration. Furthermore, new contributions in the scientific literature on excipients, including ethanol, is expected to help health professionals predict the risks of using a particular excipient, especially in the paediatric population. For example, the guideline excipients in the label and package leaflet of medicinal products for human use alerts on the risk of the use of ethanol and proposes changes on its use.

3.2.3. Propylene Glycol (PG)

PG is used as a solvent to stabilize substances that are not water soluble, in parenteral and non-parenteral formulations. It also has moisturizing, antimicrobial properties and can be used as plasticizer. It is rapidly absorbed through the gastrointestinal tract and damaged skin and metabolized in the liver to lactic acid and pyruvic acid [29].

Exposure to high doses of PG may affect the Central Nervous System, especially in new-borns and children under 4 years of age [29]. Due to children's physiological and metabolic immaturity, PG can accumulate rapidly causing toxicity [33]. In new-borns, its half-life is very long, almost seventeen hours, compared to that of adults, which is about five hours [29]. The GRAS (Generally Recognized as Safe) classification of excipients typically does not consider the differences in physiological and metabolic maturation between the paediatric and adult populations [33], a fact that justifies some important adverse reactions presented by PG in the paediatric population [29]:

- Hyperosmolar syndrome in burnt children with topical arsenic sulfadiazine ointment containing PG.
- Precipitation of irreversible deafness in preterm infants who received a multivitamin complex containing PG.
- Parenterally it is possible to observe haemolysis, seizures, respiratory depression, hypertension.
- Contact dermatitis is topically observed.

In the 1980s, cases of biochemical abnormalities, including hyperosmolarity, lactic acidosis and elevated levels of creatinine and bilirubin, were documented after exposure to 3 g/day of PG and for at least 5 consecutive days. Clinical symptoms, including seizures and bradycardia episodes [33], then appeared. In 2011, the U.S. FDA reported health problems in premature new-borns associated with the use of Kaletra[®] (lopinavir/ritonavir) solution; liquid preparation containing high amounts of PG and ethanol [33,34].

Exposure to PG in new-borns and children under 4 years of age remains common, despite historical and contemporary reports dealing with toxic adverse effects of this excipient. Thus, the study of Allegaert J. [33] in terms of the PG research project in new-borns is of great interest, as it provides scientific evidence on the tolerance and plasma clearance of this excipient, including differences in elimination pathways (renal pathway compared to the hepatic pathway).

3.2.4. Glycerol

Glycerol, a mandatory excipient (E-422), is used as solvent, sweetener, viscosizer and preservative.

When used at high concentrations (more than 40%), it can cause mucositis in the stomach, as well as diarrhoea and electrolyte disturbances due to its hygroscopic and osmotic properties. Therefore, a maximum amount of 10 g/dose [1,29] has been established.

In the adult population glycerol has few adverse effects. However, cases of neurological toxicity have been reported in the paediatric population [29].

3.2.5. Polyethylene Glycol (PEG)

PEG is a polar and water-soluble substance used as a co-solvent, suspensor and viscosity agent. The PEG 400 is the most used in liquid formulations. It may cause some laxative effect when taken orally, with the maximum daily dose established in adults at 10 mg/kg/day [1].

PEG has low oral bioavailability and renal elimination. Due to its properties, significant adverse effects such as diarrhoea and nephrotoxicity have been reported, so the maximum recommended daily dose is 10 mg/kg body weight [1]. It can also cause some laxative effect when taken orally. When new-borns and infants are exposed to high doses of PEG, gastrointestinal disorders, adverse effects typical of alcoholic solvents may occur [1,28].

3.3. Coating Agents

Phthalates

Phthalates play a primary role as a coating agent (film-forming, plasticizer) in medicinal formulations.

Exposure of pregnant women to phthalates has been associated with abnormalities in the development of the foetus, such as cleft palate and skeletal malformations; abnormalities that can end in stillbirth. It was observed that they have a high potential to produce toxicity in the development of experimental animals, as well as in their reproduction [28].

Due to these risks of certain phthalates to health, in March 2012, the CDER published a guide to orient the pharmaceutical industry on the use of phthalates: "Limiting the use of certain phthalates as excipients in CDER regulated products". This guidance document recommends limiting the use of certain phthalates, such as dibutyl phthalate (DBP) and di(2-ethylhexyl) phthalate (DEHP) [28].

3.4. Preservatives

Preservatives are a group of excipients that prevent microbial growth and, consequently, the degradation of the active substance and the possible alteration of the organoleptic characteristics of the final formula [35].

The American Academy of Paediatrics does not recommend the use of preservatives in reparations for patients under 3 years of age due to the lack of physiological and metabolic maturation of these patients. This lack of maturation may lead to the accumulation of preservatives in the liver, a fact that increases the risk of cardiovascular collapse, in addition to producing non-specific reactions or even allergies [1,35]. It should be noted that preservatives are not contraindicated in children under 3 years of age, but should only be used in imperative cases [1].

3.4.1. Sodium Benzoate

Sodium benzoate is a preservative widely used in pharmaceutical and cosmetic formulations, at concentrations between 0.02% and 0.05% [29]. Its maximum activity occurs in weakly acidic pH 4.5 solutions and is inactive at pH values greater than 5 [35].

As side effects, it can cause contact hives and other allergies. In premature children, its use is contraindicated, as it presents a risk of metabolic acidosis and jaundice [29,35].

One of the large prospective studies conducted by Nellis and collaborators [36,37] in hospitalized neonates in Europe described the administration of eight potentially harmful excipients of interest (EOI) (parabens, polysorbate 80, propylene glycol, benzoates, sodium saccharine, sorbitol, ethanol and benzalkonium chloride) and identified risk factors resulting from exposure. Neonates appear to lack the ability to conjugate benzoates with glycine, leading to the accumulation of benzoic acid that can cause metabolic acidosis and neurotoxicity [26,27].

The ESNEE (European Study of Neonatal Exposure to Excipients) clinical study [38] showed that sodium benzoate was found in 10 medicines given to new-borns, despite being a highly toxic excipient to them. Preservatives such as parabens (and their sodium

salts) and propyl para-hydroxy-benzoate were also found in 24 paediatric medications, and ethanol in 8.

3.4.2. Benzyl Alcohol

Benzyl alcohol presents antibacterial properties. For that reason, it is used as a preservative in a lot of medicines. Its activity depends on the pH; being at it is maximum at a low pH (between 2.5–4.5). It is used at the concentration of 0.01–0.15% in oral preparations [35].

In adults, it is metabolized to benzoic acid, which is conjugated in the liver with glycine. As a result, the acid hippuric formed is excreted in urine. However, in new-borns, this conversion of the benzoic acid into hippuric acid is very diminished, because of the lack of liver maturation. That justifies fatal intoxication cases in new-borns who had their umbilical catheters cleaned with benzoic acid. Consequently, cases of metabolic acidosis and respiratory depression occurred. Additionally, other adverse effects have been described, like intraventricular bleeding, cerebral palsy and developmental delay. In some cases, there have been reactions of hypersensitivity, allergy and contact dermatitis [29,39–41].

In the 1990s, Svinning and collaborators [42] conducted a review of the medical records of babies who weighed less than 1250 g at birth and were admitted to the neonatal intensive care unit. The main objective of this study was to assess the impact of the toxicity of benzyl alcohol, following discontinuation of the use of solutions to wash intravascular catheters containing benzyl alcohol. A significant decrease in mortality rate and incidence of Grade III/IV intraventricular haemorrhage was observed among infants weighing less than 1000 g at birth who were not exposed to benzyl alcohol (as opposed to those who were).

The maximum dose of benzoic acid (and other benzoates, calculated as benzoic acid) recommended by WHO is 5 mg/kg body weight per day in adults, a dose that, in children, logically, should be much lower [29,35]. As the effects on new-borns are severely toxic, the U.S. FDA has recommended the exclusion of benzyl alcohol from medications, intravenous fluids, and heparin washing solutions for them [36]. The EMA states that any medicine containing benzyl alcohol “should not be given to premature babies and new-borns” [42,43]. In fact, currently, any exposure to benzyl alcohol is contraindicated in children under 3 years of age [44].

3.4.3. Benzalkonium Chloride

Benzalkonium chloride is a quaternary ammonium used in ophthalmic preparations at a concentration of 0.01–0.02% (*v/v*). Generally, it is non-irritating or sensitizing and is well tolerated in skin solutions.

As a side effect, it can cause bronchoconstriction in asthmatic patients, if used in nebulization solutions. Furthermore, cases of ototoxicity may occur in otic preparations, hypersensitivity in topical skin preparations and respiratory failure in infants who ingest this excipient, with this side effect being the most severe [29].

3.4.4. Thiomersal

Thiomersal is a preservative widely used in vaccines and topical preparations, such as eye drops. Its toxicity is similar to mercury: in fact, it contains a mercury atom in its molecular structure. The concentration used depends on the medicinal product: in injectable preparations 0.01% is used and in ophthalmic solutions between 0.001% and 0.15% [30].

Several allergic hypersensitivity reactions (e.g., erythema, vesicles) have been reported. Therefore, health authorities have recommended their withdrawal from vaccines at risk of toxicity. Recently, thiomersal has also been implicated in the onset of autism spectrum disorders in children who received aluminium salt vaccines as an adjuvant. Accordingly, various countries (including Spain) no longer market paediatric vaccines with this component [29]. The use of single-dose vials is recommended in many cases to prevent the use of preservatives such as thiomersal or sulphites such as sodium metabisulphite [28].

3.4.5. Parabens

Parabens are the most commonly used preservatives (also in cosmetics and foods), due to their wide antimicrobial spectrum and their effectiveness over a very wide pH range (between 4 and 8) [29,35].

Parabens are of mandatory declaration. They are used at concentrations between 0.01 and 0.2% [45], although it is most common to use a mixture in proportion 10:1 (0.2% methylparaben + 0.02% propylparaben). The maximum recommended daily dose is 10 mg/kg body weight [35].

They may produce a cross-hypersensitivity reaction in patients allergic to aspirin. This is because the main metabolite of parabens is hydroxyparabenzoic acid, structurally very similar to aspirin [29].

Recent pharmacovigilance studies have highlighted certain questions about the purported safety (non-teratogenic or carcinogenic) of parabens [29]. Alternatives should therefore be found, especially in paediatric formulations. Antimicrobials are not necessary for parenteral formulations. The absence of parabens and benzoates in 85% of parenteral prescriptions suggests that administration of these excipients can be largely avoided [36].

3.5. Antioxidants

Antioxidants are a group of chemical compounds used to prevent oxidation of the active substances in formulations [29].

3.5.1. Sulphites

Sulphites are antioxidants widely used in different formulations; sodium sulphite, sodium bisulfite, sodium metabisulphite and potassium metabisulfite [29] are the most common.

Regulatory agencies (e.g., FDA, EMA) consider excipient sulphites safe. However, they present risks and possible fatal side effects derived of their use. One of the most common cases occurs in asthmatic patients, who may develop severe bronchospasm if they take medicines containing sulphites in their formulation [29].

The antioxidants constitute a group of compound chemists used to avoid the oxidation of the active principles in the formulations [29].

It should be noted that a large number of people are sensitive to sulphites and may experience a variety of symptoms, including dermatological, gastrointestinal and respiratory symptoms. However, reactions that develop in the respiratory tract explain most cases of sensitivity to sulphites. It is important to note that several individuals experience a variety of symptoms after exposure to sulphites; therefore, skin, intestinal and respiratory reactions can occur simultaneously and in various combinations and severity. People with sensitive skin who regularly use cosmetics or topical medications containing sulphites have chronic skin symptoms, especially on the hands, perineum and face. Sensitivity to sulphites is a very real problem that significantly affects the health of many people, especially asthmatics. Sensitivity to sulphites should be considered when people show adverse reactions to a variety of exposures, without an obvious pattern, particularly when those people experience worsening asthma symptoms after consumption of foods such as dried fruits and wines, or adverse skin reactions, after the use of cosmetics or medicinal creams [46].

3.5.2. Propyl Gallate

Propyl gallate is an antioxidant used to prevent the breakdown of fatty acids. It is used at a concentration of 0.1% and also has a synergistic effect with other antioxidants. In neonates it can cause dermatitis, skin allergy and methemoglobinemia [29].

3.6. Sweeteners

The use of sweeteners varies between routes of administration and, like preservatives, are not necessary in parenteral administrations [36,37]. They have been linked to photosensitivity reactions, diarrhoea and poor absorption of nutrients [36,47].

The most commonly used sweeteners in pharmaceutical formulations are sucrose, sorbitol, mannitol, aspartame and sucralose.

3.6.1. Sucrose

Sucrose is a natural disaccharide that is hydrolysed in the gut into two monosaccharides: glucose and fructose.

In children with type I diabetes, the use of sucrose should be avoided. Very high concentrations (up to 35% are used for liquid formulations such as syrups). When the patient needs prolonged treatment with these preparations, he or she is at risk of dental damage. It has also been described that administration at very high doses on a daily basis may be carcinogenic [29].

3.6.2. Sorbitol

Sorbitol is a monosaccharide that is not absorbed into the digestive tract and is therefore considered safe in paediatric patients, although it is laxative at high doses. It is also used as a diluent as well as capsule plasticizer [29].

Sorbitol is another example of an excipient that causes gastrointestinal disorders, such as abdominal pain, swelling, flatulence, vomiting and osmotic diarrhoea. Because sorbitol is metabolized to fructose, it should be avoided on children with fructose intolerance and hypoglycaemia. In isolated cases it can cause liver damage leading to coma and even death [28–30].

In infants the accumulation of sorbitol can lead to diabetic complications such as retinopathy and cataracts. Therefore, the amount of sorbitol is limited to 0.3 mg/kg in paediatric formulations [28].

3.6.3. Mannitol

Mannitol is used as a sweetener and as a diluent. It has been linked to severe anaphylactic reactions in paediatrics [29]. As in the case of sorbitol, it is not absorbed into the digestive tract, so it has laxative properties at high doses.

3.6.4. Aspartame

Aspartame is an artificial sweetener that has 180 and 200 times more sweetener power than sucrose. Because of this, it is the most used sweetener in the pharmaceutical and food industry. It is a disaccharide made of an aspartic acid and a methyl phenylalanine ester. It is an excipient of mandatory declaration and its maximum dose has been set at 40 mg/kg body weight [29,35].

Phenylalanine is very harmful for patients with phenylketonuria, as well as for pregnant mothers who carry a foetus of such metabolopathy. The use of aspartame in patients with phenylketonuria should be avoided. The adverse effects of aspartame that have been described are: neurological (neurotoxicity, epilepsy, headache, panic attack and hallucinations), hypersensitivity reactions (vascular and granulomatous panniculitis) and cross-reaction with sulphonamides [29].

3.6.5. Saccharine

Saccharine is also an artificial sweetener 300–600 times stronger than sucrose, but if not used properly it can leave a residual bitter taste. Your daily dose should not exceed 2.5 mg/kg body weight. It is recommended to limit the daily dose in children and pregnant women [29,48].

Currently, controversy about its safety remains present, as in adults it has been linked to bladder cancer when used at very high doses. Adverse effects of saccharine include hives, itching, photosensibilization, eczema, as well as nausea and diarrhoea [29].

3.6.6. Sucralose

Sucralose has a sweetener power between 100 and 300 times higher than sucrose. Its maximum daily dose is 15 mg/kg in weight.

Sucralose is a non-toxic compound and is also not irritating, but it is not considered totally inert. It can increase the expression of cell flow transport protein glycoprotein P and two cytochrome P450 isoforms, which are essential substances in the drug purification process.

Furthermore, sucralose alters the composition of the microbiome of the digestive tract, which ends up causing the reduction of the proportion of beneficial bacteria. In addition, if cooked at high temperatures, chloropropanol can form, which is a toxic compound. It can also alter the patient's levels of glucose, insulin and glucagon-like peptide type 1 (GLP-1) [29].

3.7. Surfactants

Polysorbates

Polysorbates are partial esters of sorbitol fatty acids and their copolymerized anhydrous with ethylene oxide. They are used as dispersant agents, emulgents, non-ionic sanitary surfactants, solubilizers, and moisturizers, among other things.

In general, they are considered non-toxic and non-irritating. However, they have been associated with serious side effects, including deaths in under-weight neonates who received vitamin E preparations with this substance [25]. In addition, polysorbate 80 has been associated with increased mortality in new-borns [42].

3.8. Colorants

Colorants are excipients used to facilitate the identification of the formula by parents and patients. The most commonly used dyes are whip dyes, quinolones, triphenylmethane and xanthenes.

Tartrazine (yellow number 5) has been implicated in anaphylactic reactions, edema, asthma, bronchospasm, eosinophils, angioedema and hives in patients with sensitivity to it. It appears to cause histamine degranulation of mast cells [29]. As a result, most global regulatory agencies restrict the use of dyes such as tartrazine, because azo dyes have been linked to hypersensitivity and ADHD reactions in children. These dyes can be replaced by plant dyes such as annatto, malt beta-carotene and turmeric and should not be used at all in paediatric formulations [28].

3.9. Excipients not Recommended in Paediatrics and Paediatric Formulations

To investigate the exposure of children to excipients not recommended at an early age, a compilation of paediatric formulations (nationally and internationally) was made (see Appendices C–F). As will be seen below, most of these formulations contain some excipient not recommended in paediatrics:

In Appendix C, there is a summary table (Table A2) of examples of solid and semi-solid medicines used in the paediatric population, marketed in Spain. Additionally, a list of excipients and relevant characteristics of the pharmaceutical form (PF) is shown (performed consultation of CIMA database, September 2020). It clearly shows that the reason such excipients are not recommended for the paediatric population is because of the adverse effects they may cause, which include:

- Approximately 100% of the formulations shown here carry at least one excipient not recommended for the paediatric population.
- Benzalkonium chloride, methyl para hydroxybenzoate and propyl para hydroxybenzoate are some of the most commonly used preservatives in solid and semi-solid formulations for paediatric use, even though they are considered to be potentially toxic in neonates.
- Sucrose, aspartame and mannitol are used as sweetener. 100% of the oral solid formulations collected in Table A4 carry at least one excipient of these: 40% of formulations carry mannitol and aspartame; 20% carry the 3 excipients; 20% sucrose and aspartame and the remaining 20% only sucrose.
- Propylene glycol is another excipient commonly used in solid formulations as a solvent, moisturizer and preservative. Caution should be exercised in children under 4 years of age and neonates, as propylene glycols, at high doses, may cause alterations in the Central Nervous System, in addition to other side effects discussed in the previous sections of this paper.
- Microcrystalline cellulose, methylcellulose and ethyl cellulose are one of the most commonly used excipients in solid formulations. They have no major side effects, but in high amounts they can cause a laxative effect.
- Most of the solid formulations collected in Table A2 use flavourings such as grape essence, lemon flavouring, caramel cream aroma or orange essence, in order to achieve a better palatability. The main drawback of their incorporation into paediatric formulations is that they usually have a complex and poorly known composition [49].
- Lanolin is an excipient used in pastes and ointments, which are frequently used in the paediatric population. This excipient may cause skin hypersensitivity reactions, which is why caution should be exercised in patients with known sensitivity issues [50].

Appendix D (Table A3) lists marketed liquid formulations suitable for the paediatric population. Liquid formulations are the most common in paediatrics because of their easy administration. The need for at least one liquid formulation of any drug indicated in the paediatric population is becoming increasingly noticeable. Not all active principles are soluble or stable in water. Therefore, excipients are used in liquid formulations to improve the solubility of certain active principles and/or increase their stability. The problem is that most excipients found in adult formulations should not be used in paediatrics. However, as shown in Table A3, there are a wide variety of marketed formulations indicated in paediatrics that contain these non-recommended excipients:

- Ethanol, sorbitol and propylene glycol, despite being contraindicated in paediatrics, especially ethanol, are still included in some paediatric formulations.
- The addition of non-recommended sweeteners, such as sucrose, sucralose or sodium saccharine, is also seen in these paediatric formulations.
- The addition of preservatives in paediatric formulations should be avoided as much as possible, and if necessary, in the least amount. Parabens are among the safest preservatives in paediatrics, yet others that are not recommended are still used (e.g., Table A3: sodium benzoate, benzoic acid and benzyl alcohol). Benzalkonium chloride, despite not being recommended for asthmatic patients, is used for the formulation of most eye drops, nasal drops and gothic drops.

Appendix E (Table A4) and Appendix F (Table A5) provide examples of FDA-registered drugs (liquids and solids) and liquid formulations in paediatric use research, respectively. Like the other examples provided, these medicinal products and liquid formulations contain at least one excipient not recommended for the paediatric population, such as propylene glycol, polysorbates, methyl or propyl para hydroxybenzoate, benzyl alcohol, benzoic acid, ethanol or sucralose, among others.

- Excipients not recommended for paediatric population are most commonly used in oral solutions and suspensions (referred to in Tables A4 and A5, propylene glycol, benzoic acid, polyethylene glycol, polysorbate 80 and sodium benzoate).
- Like the other examples, there is also frequent use of sweeteners (fructose, sucrose, sucralose, aspartame and sodium saccharine).
- Benzalkonium chloride is one of the most commonly used preservatives in ophthalmic and nasal drops, as shown in Table A4. It is usually a safe excipient, but can cause serious adverse effects, such as bronchoconstriction in asthmatic patients, ototoxicity in erotic preparations or respiratory failure in infants who ingest this excipient, this adverse effect being the most severe.

4. Promising Pharmaceutical Form in the Paediatric Population: ODT and 3D Drug Printing

The development of Orally Disintegrating Tablets (ODT) has received greater interest among researchers and the pharmaceutical industry over the past decade. ODT tablets are designed to dissolve quickly upon contact with saliva, in the absence of additional water, compared to traditional tablets [51].

ODT tablets offer several advantages, combining the properties of solid and liquid formulations. They are quickly ingested when inserted into the tongue, eliminating the need to chew the tablet, swallow it intact or take it with water. Currently, they are a widely accepted form of dosing, especially for patients who have difficulty swallowing (paediatric and geriatric), and for the treatment of patients where therapeutic compliance is difficult [51,52].

As a result of the rapid disintegration of ODT tablets, the active substance comes into contact with taste buds, so a key aspect to consider in these formulations is palatability. It is necessary to mask the taste of bitter active ingredients in order to develop successful formulations. In the past, sweeteners and aromas were used as methods of flavour masking in dispersible or rapidly disaggregation tablets. However, these additives were not a sufficient means to completely mask the taste. Currently, with scientific and technological advances, different dosing alternatives are available to mask the taste, such as freeze-drying, microencapsulation, fluid bed coating or coating in supercritical fluids [51].

It should be mentioned that there is an innovative tool for pharmaceutical pre-formulation of ODT tablets. This tool makes it possible to predict whether a disintegrating excipient or a mixture of excipient powder + active substance is suitable for obtaining an oral dispersible tablet by direct compression or not: the new model SeDeM-ODT [53].

The SeDeM-ODT model (based on the SeDeM expert system) indicates the ability of a powder to be compressed, providing the Good Compressibility and oral dispersibility Index (IGCB). This index is composed of six main factors which indicate whether a powder mixture has the ability to be compressed by direct compression. Furthermore, it indicates whether the tablets are suitable for formulation as oral dispersible tablets. Thus, the SeDeM-ODT model facilitates the selection of excipients with the appropriate properties to produce ODT tablets using direct compression technologies [53].

Figure 1 will detail several special features and advantages of ODT tablets [52,54].




Figure 1. Characteristics and advantages of ODT tablets.

Figure 2 specifies the most noteworthy drawbacks of ODT tablets [54].

On the other hand, the technical disadvantages associated with the manufacturing process of ODT tablets could be solved by three-dimensional drug printing technology. Generally speaking, this technology is supported by the following processes: a program capable of generating a file is required with the necessary information for printing the drug. This same program (also present on the computer that will control the printer) must be able to read the instructions contained in the generated file and convert it into precise commands for the 3D printer to generate the part [55].




Figure 2. Disadvantages of ODT tablets.

The response to drugs may be different among patients, due to inter-individual variability, caused by both genetic and environmental factors. Accordingly, “patient-specific” or “tailor-made” dosage concepts could be an alternative to mass production in the traditional pharmaceutical industry. In this approach, 3D printing has proven to be a manufacturing technique with great potential, as it allows the creation of three-dimensional objects, layer by layer, with total freedom of form and design. Thus, obtaining customized pharmaceutical forms is one of the main objectives of 3D printing in the pharmaceutical sector [55].

Paediatric patients are one of the population groups with the greatest need for personalized dosing adapted to their requirements (age, weight, pathological status, etc.). However, most 3D printed drugs are solid oral formulations, which are not suitable for this population group. Medicinal gummies developed through 3D printing (tailor-made to the patient) could be a form of oral dosing suitable for paediatric patients, due to their striking appearance and pleasant organoleptic characteristics [55].

New advances in obtaining medicines and medical devices, using 3D printing technology, have generated novel perspectives in the processes of obtaining these products. At present; however, several issues are perceived that will need to be resolved as the perfection and implementation of this technique progresses, in order to make it a common process of obtaining medicines and medical devices.

5. Conclusions

The critical study suggests that excipients are often used at higher concentrations than recommended in international paediatric guidelines, and with inappropriate labelling, increasing the potential risks associated with the various excipients discussed [26].

Indeed, the pharmacokinetic and pharmacodynamic profiles of the child population vary substantially, with paediatric safety profiles related to the age and development of excipients often differing from those of adults [48]. The most toxic excipients in neonates are known to be sodium benzoate, propylene glycol, methyl para hydroxybenzoate, propyl, sodium saccharine, benzyl alcohol, benzalkonium chloride, polysorbate 80 and ethanol [56]. However, these excipients are used in formulations according to the study conducted.

European new-borns receive several potentially harmful pharmaceutical excipients: parabens, polysorbate 80, propylene glycol, benzoates, sodium saccharine, sorbitol, ethanol and benzalkonium chloride. According to the study conducted by Nellis and collaborators [36], there are regional variations in the neonatal administration of these potentially harmful excipients. This suggests the possibility of reducing exposure to parabens, polysorbate 80, propylene glycol and sodium saccharine by replacing it with products without these excipients. However, a joint effort by the regulatory authorities on medicines, in

particular the paediatric committees, will be necessary. Current therapeutic options for the paediatric population justify further toxicokinetic and drug safety studies so that they are tailored to the special needs of the paediatric population.

In general, there is little information regarding excipients in paediatrics. It is of the utmost importance to develop new research related to the safety and toxicity of excipients to reduce the prevalence of adverse effects in paediatric populations. Gallon formulators can formulate safer, more stable and higher quality products. Furthermore, the possible adverse effects of the active ingredients and the excipients used in the paediatric population should be reconsidered—since excipients that are safe in adults—may have potentially toxic effects in children.

Finally, the development of databases such as STEP is relevant and beneficial for the development and use of drugs in paediatrics. Additionally, the SEEN project is relevant both nationally and internationally, as it reveals the current status of excipients and takes into account the frequency and quantity (in terms of medicines given to new-borns and young children).

Author Contributions: Conceptualization, P.P.-L. and E.G.-M.; methodology, J.M.S.-N.; investigation, K.R. and B.C.-R.; writing—original draft preparation, K.R. and B.C.-R.; writing—review and editing, A.N.-R. and E.G.-M.; visualization, D.M.-F. and M.S.-P.; supervision, P.P.-L. and E.G.-M.; project administration, J.M.S.-N. All authors have read and agreed to the published version of the manuscript.

Funding: The corresponding author, Blanca Chiclana-Rodríguez, acknowledges the financial support of the Generalitat de Catalunya for the PhD scholarship FI-DGR (CVE-DOGC-A-19269057-2019).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on the Reference list.

Acknowledgments: Renato Francis de Souza Pereira is thanked for helpful discussions during the finalization of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A. Purposes of the STEP Database

More specifically, the purposes of the STEP database are [22] to:

1. Serve as a public base for evidence regarding the safety and toxicity of excipients in order to allow the pharmaceutical industry, academics, pharmacists, physicians and regulators to make informed decisions.
2. Improve prospects of identifying potential security issues in the early stages of the development process when excipients are selected.
3. Help highlight any relationships between exposure and evidence of clinically significant toxicity in the paediatric age group in general, or in paediatric subpopulations.
4. Identify possible differences in expression, types or patterns of toxicity in children compared to adults. Provide a basis for assessing the need to generate new data for paediatric medicines (e.g., bridge studies, juvenile toxicity studies, etc.), in order to clarify what kind of new data, knowledge gaps or studies may be needed.
5. Support companies with their regulatory presentations with easily available information.
6. Support and improve research activities by providing a platform to share unreleased data and available data with corporate entities.

Appendix B

Table A1. Most important characteristics of the excipients discussed in this paper (in alphabetical order).

| Excipient | Functions | DAI * | Recommendations | Adverse Effects | References |
|-----------------------|--------------------------|-------------------------|--|--|---------------------|
| Aspartame | Artificial Sweetener | 40 mg/kg | - Contraindicated in patients with phenylketonuria | - Neurological involvement: neurotoxicity, epilepsy, headache, panic attack, hallucinations - Hypersensitivity reactions: vascular, granulomatous panniculitis - Cross reaction with sulfamides | [29,35] |
| Benzalkonium chloride | Preservative | NA | - Caution in asthmatic patients | - Bronchoconstriction - Ototoxicity - Hypersensitivity | [29] |
| Benzyl alcohol | Preservative | 5 mg/kg | - Contraindicated in children under 3 years of age by immature their metabolism | In new-borns and children under 3 years of age cause: - Metabolic acidosis and respiratory depression - Intraventricular haemorrhage - Cerebral palsy and developmental delay - Hypersensitivity reactions | [29,35,36,39–44] |
| Ethyl alcohol | Solvent and preservative | 6 mg/kg/dose (<6 years) | Paediatric formulations should not exceed the following limits of ethanol: - In children over 12 years of age: less than 10% (v/v) - In children 6–12 years old: less than 5% (v/v) - In children under 6 years of age: less than 0.5 (v/v) | - Hypoglycaemia, acidosis and hydroelectrolytic alterations - Stupor, coma respiratory and CNS depression, cardiovascular toxicity | [17,26,27,29,31,32] |

Table A1. Cont.

| Excipient | Functions | DAI * | Recommendations | Adverse Effects | References |
|---------------------|---|-----------|--|---|------------|
| Glycerol | Solvent, sweetener, viscosizer and preservative | 10 g/dose | <ul style="list-style-type: none"> - Caution in paediatric population - Do not exceed the safe daily dose (1.0–1.5 g/kg body weight) | <ul style="list-style-type: none"> - Mucositis in the stomach - Diarrhoea and electrolyte disturbances | [1,29] |
| Lactose | Diluent | NA | <ul style="list-style-type: none"> - Caution in patients with lactose intolerance - Contraindicated in galactosemia | <p>Symptoms of lactose intolerance: severe abdominal pain, flatulence, bloating or swelling and diarrhoea.</p> <ul style="list-style-type: none"> - Systemic symptoms such as muscle and joint pain and eczema - In children it can cause dehydration, bacterial proliferation and metabolic acidosis | [1,28] |
| Parabens | Preservative | 10 mg/kg | <ul style="list-style-type: none"> - It is recommended to avoid its use in neonates | <ul style="list-style-type: none"> - Cross hypersensitivity reactions in patients allergic to acetylsalicylic acid - Hyperbilirubinemia in new-borns | [29,35,36] |
| Phthalates | Coating agents (plasticizers) | NA | <ul style="list-style-type: none"> - Not recommended for use in pregnant women or children under 3 years of age | <ul style="list-style-type: none"> - Anomalies in the development of the foetus: cleft palate and skeletal malformations. May lead to stillbirth | [28] |
| Polyethylene glycol | Solvent, suspensor and viscosity agent | 10 mg/kg | <ul style="list-style-type: none"> - Caution in new-borns and infants | <ul style="list-style-type: none"> - Nephrotoxicity - Gastrointestinal disorders - Laxative effect | [1,28] |

Table A1. Cont.

| Excipient | Functions | DAI * | Recommendations | Adverse Effects | References |
|------------------|---|---|---|---|------------|
| Polysorbates | Dispersing, emulgent, surfactants, solubilizing and moisturizing agents | NA | - Caution in new-borns | - Serious adverse effects: deaths in low-weight neonates who received vitamin E preparations with polysorbates. - Polysorbate 80: increased mortality in new-borns | [25,42] |
| Propyl gallate | Antioxidant | NA | - Caution in new-borns | - In neonates it can cause dermatitis, skin allergy and methemoglobinemia | [29] |
| Propylene glycol | Solvent, moisturizing and preservative | - Neonates: 1 mg/kg - Under 5 years: 50 mg/kg - Adults: 500 mg/kg | - It is recommended to avoid in children under 4 years of age because of lack of metabolic maturation | - CNS depression - Laxative effect from high osmolality after oral administration | [29,33,34] |
| Saccharine | Sweetener | 2.5 mg/kg | - It is recommended to limit the daily dose in pregnant women and children | - Urticaria, itching and eczema - Photosensitization - GI disturbances: Nausea and diarrhoea | [29,48] |
| Sorbitol | Sweetener and diluent | - Children 0–2 years 5 mg/kg - Over 2 years: 140 mg/kg | - Contraindicated in patients with fructose intolerance - Not recommended for use in patients with hypoglycaemia | - Gastrointestinal disorders - It can cause hepatic damage with comma and even death | [28–30] |
| Starch | Diluent and added | NA | - Conservation in dry environment - Well tolerated by children | - In case of moisture, carcinogenic aflatoxins may occur | [29] |

Table A1. Cont.

| Excipient | Functions | DAI * | Recommendations | Adverse Effects | References |
|---|--------------|----------|---|---|------------|
| Sucralose | Sweetener | 15 mg/kg | - Caution in patients with metabolic disorders | Alters the composition of the digestive tract microbiome - At high temperatures chloropropanol may form - May alter glucose, insulin and GLP-1 *2 levels | [29] |
| Sucrose | Sweetener | NA | - Not recommended for use in children with type I diabetes | - Dental damage - At very high doses on a daily basis I could be carcinogenic | [29] |
| Sulphites | Antioxidant | NA | - Avoid in asthmatic patients | - Hypersensitivity and bronchospasm reactions | [29] |
| Tartrazine, quinolines, triphenylmethane, xanthines | Colorants | NA | - It is recommended not to use them in paediatric formulations | - Hypersensitivity reactions in patients' sensitive to tartrazine - Azo colorants: cross-sensitivity reactions with acetylsalicylic acid Erythromycin: photosensitization reactions | [28,29] |
| Thiomersal | Preservative | NA | - Avoid use in vaccines as a preservative due to its side effects | - Hypersensitivity reactions - Autism spectrum disorders | [28,29] |

* ADI: Admissible Daily Intake; *2 GLP-1: Glucagon Like Peptide; NA: Not Available.

Appendix C

Table A2. Examples of solid and semisolid medicines used in Spain for paediatric population: List of excipients and relevant characteristics of FF (Performed consultation of CIMA database, September 2020).

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------|------------|---|--|--|--|
| SOLID PREPARATIONS | POWDERS | Example 1: Amoxicillin Normon 250 mg/5 mL EFG Oral Suspension Powder | Amoxicillin | <ul style="list-style-type: none"> - Powders are administered after prior dissolution. - They are little employed in the paediatric population; present the drawback that it is difficult to mask the bad taste. | [29,57,58] |
| | | Example 2: Azithromycin Sandoz 200 mg/5 mL EFG Oral Suspension Powder | Azithromycin | <ul style="list-style-type: none"> - Risk of accidental aspirations. - They are usually used in master formulation and for the administration of antacids. | |
| | GRANULATED | Example 1: Paediatric Gelocatil 325 mg Granules | Calcium carbonate, Sodium hydrogen carbonate, Citric acid anhydrous, Anhydrous sodium citrate, Aspartame (E-951), Sucrose, Mannitol (E-421), Amorphous silica, Glycerol die-stearate type 1, Croscarmellose sodium, Sodium glycolate starch type A (potato starch) gluten-free, Ethyl cellulose, Hydroxypropyl methylcellulose and Polyethylene glycol 400 | Paracetamol | <ul style="list-style-type: none"> - Granules are more stable and fluid than powders. - The most used are effervescent granules, which in the presence of water react by releasing carbon dioxide, which protects the stomach and partly anesthetizes taste buds. - They should be completely dissolved prior to administration in order to reduce bicarbonate intake. - Children are often pleased by their resemblance to certain refreshing drinks. |

Table A2. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References | |
|-----------------------|--------------------------------------|---|--|-------------------------------------|--|------------|
| SOLID PREPARATIONS | ORAL DISPERSIBLE TABLETS (ODT) | Example 1: Apiretal 325 mg oral dispersible tablets | Ethyl cellulose, Microcrystalline cellulose, Crospovidone, Aspartame (E-951), Colloidal silica, Mannitol, Talco, Magnesium stearate and Grape essence | Paracetamol | As advantages of oral dispersible tablets, the following stand out: - They combine the advantages of liquid forms and solid oral forms. - An exact dose may be given compared to liquids. - They have a pleasant taste, thus facilitating therapeutic compliance in the paediatric population. - No need to swallow the tablet or drink water; dissolves rapidly in saliva, being an appropriate choice for patients with swallowing problems, such as children or geriatric patients. | [54,60,61] |
| | | Example 2: Junifen 200 mg lemon-flavored oral dispersible tablets | Ethyl cellulose, Precipitated silicon dioxide, Hypromellose, Mannitol, Aspartame (E-951), Croscarmellose sodium, Magnesium stearate and Lemon flavouring | Ibuprofen | - They are safe and effective and can be bio-equivalent with respect to conventional tablets. - They have rapid absorption and, therefore, a rapid introduction of the therapeutic effect. Disadvantages include: - The lack of mechanical resistance presented by traditional tablets. - The possibility of physical instability in excess moisture. - ODTs require special conditioning to ensure their stability. | |

Table A2. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------|---------------|--|--|---|------------|
| SOLID PREPARATIONS | SUPPOSITORIES | Example 1: Febectal Infants 150 mg Suppositories | Colloidal anhydrous silica, Solid semi-synthetic glycerides | Paracetamol | |
| | | | | As advantages, the following stand out: <ul style="list-style-type: none"> - Generally, they avoid gastric intolerance problems. - They are of interest when the medicine is inactive orally, the patient is unconscious or are children who refuse to swallow the medication. - They avoid inactivation by the effect of first liver step. Disadvantages include: <ul style="list-style-type: none"> - Reproducible behaviour can only be obtained if absorbed into an area two centimetres from the end of the rectum. - Absorption of the active substance may be erratic. - As it avoids the effect of first liver step, it can increase the possibility of poisoning. - In certain cultures, it is a form that is not well accepted socially. | [29,62] |

Table A2. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References | |
|-------------------------|-----------|--|--|-------------------------------------|--|---------|
| SEMI-SOLID PREPARATIONS | GELS | Example 1: Fenistil 1 mg/g Gel | Benzalkonium chloride, Disodium edetate, Carbomer, Sodium hydroxide, Propylene glycol and Purified water | Dimethindene maleate | <ul style="list-style-type: none"> - It is a semi-soft transparent colloid, with a large proportion of liquids. - Low penetration power. - Many incompatibilities with active substances. - It is easy to apply, pleasant and soothing for its refreshing properties. | [29,63] |
| | CREAMS | Example 1: Perme-Cure 5% Cream | Butylhydroxytoluene (E-321), Castor Oil, Deionized water, Steareth-2, Cetareth-2-Phosphate, Sosa to the 20 %, Vitamin E acetate, Phenonip, Citric acid, Disodium edetate and Scent | Permethrin cis:trans (25:75) | <p>As advantages, the following stand out:</p> <ul style="list-style-type: none"> - Comfortable and easy application. - Provide a controlled release of the active substance. - They act as emollients and moisturizers, due to their composition | [64] |
| SEMI-SOLID PREPARATIONS | OINTMENTS | Example 1: Oftacilox 3 mg/g Ophthalmic Ointment | Liquid paraffin and White Vaseline | Ciprofloxacin | <ul style="list-style-type: none"> - Ointments are forms of external use intended to be administered by gentle friction on a surface of the body, to achieve a local action or with the aim of penetrating the drug through it. - In many cases, the topical route is a route of absorption comparable to oral or other, so the dosage and duration of treatment must be very well specified. New-borns and infants have a very increased skin-to-weight ratio. Coupled with the fact that at this age the skin is very permeable, it makes them especially vulnerable to toxic frames by ointments. | [29,65] |

Table A2. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References | |
|----------------------------|--|---|---|---|---|---------|
| PASTES | Example 1: Anti-congestive Cusi (Paste Lassar) | Lanolin (wool fat), Liquid Vaseline and Stringy Vaseline | - Zinc oxide - Corn starch | - This is a suspended ointment. - They are used when you want to locate the action of the active substance to a specific area, as they are irritating and staining. | [29,66] | |
| SEMI-SOLID PREPARATIONS | NON-CREAM EMULSIONS | Example 1: Lactisona 10 mg/mL Skin Emulsion | Carbomer 940, 1,3-dimethylol-5,5-dimethyl hydantoin, Dihydro-acetic acid, Pyrrolidone sodium carboxylate, Lactic acid, Sodium hydroxide, Stearyl alcohol, Glycerol stearate, Cetyl alcohol, Isopropyl palmitate, Mineral oil, Myristyl lactate, Fragrance and Water | Hydrocortisone | - Emulsions are a dispersed system, stabilized by the addition of an adequate emulsifier, two immiscible phases, where both the internal and external phases are liquid. - The emulsions enable fat-soluble and water-soluble active ingredients to come into contact with the skin simultaneously, encompassing each of them in the phase of the emulsion for which they have the greatest affinity. - Patients or users of topical application preparations often prefer emulsion vehicles to those of any kind. | [50,67] |

Appendix D

Table A3. Examples of liquid medicines used in paediatrics: List of excipients and relevant characteristics of Pharmaceutical Form.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References | |
|---------------------|--|---|--|--|--|---------------|
| LIQUID PREPARATIONS | ORAL SOLUTIONS | Example 1: Diazepam 2 mg/5 mL Solution without sugar | Sodium Docusate, Aluminium silicate and Magnesium, Propylene glycol, Raspberry Flavour, Sodium Saccharine, Precool Erythrosine (E127), Sorbic Acid (E200), Propyl para hydroxybenzoate, Methyl para hydroxybenzoate, Sorbitol, Liquid (Non-Crystalized) (E420) and Glycerol (E422) | Diazepam | <p>As advantages, the following stand out:</p> <ul style="list-style-type: none"> - Release of the active substance(s) much faster than in solid forms. - The dosages are correctly expressed in milligrams, micrograms and U/mL, allowing them to be adapted to the child's weight. - Easy and comfortable dosing, as it is in volume (spoons, drops, etc.) - Less irritation effect if it is an aggressive medicine, at the gastric level, as it is dampened by dilution. - Solutions, suspensions or emulsions are obtained, depending on the size of the particles of the internal phase. <p>As disadvantages they present:</p> | [29,49,68–70] |
| | | Example 2: Paracetamol Level 100 mg/mL Oral Solution | Citric acid, Sodium hydroxide, Sucrose, Propylene glycol, Macrogol, Strawberry Essence, Cochineal Red A (Ponceau 4R) (E-124), Hydrochloric Acid 5 N and Purified Water | Paracetamol | | |
| | Example 3: Diazepam IntenSol™ Oral Solution 5 mg/mL <i>* Do not use in children under 6 months of age</i> | Alcohol, Yellow D&C 10, Polyethylene glycol, Succinic Acid and Water | Diazepam | | | |
| | Example 4: Prednisolone 10 mg/mL Oral Solution | Sodium Methyl para hydroxybenzoate, Sodium Propyl para hydroxybenzoate, Glycerol, Sodium Saccharine, Sodium Edetate, Sodium Aqueous solutions of medicinal substances that are Dihydrate, Orange flavour (contains propylene glycol), Sodium hydroxide and Purified Water | Prednisolone | <ul style="list-style-type: none"> - Greater ease and possibility of contamination than solid pharmaceutical forms, which forces the addition of preservatives. | | |

Table A3. Cont.

| Pharmaceutical Form | Excipients | API | Pharmaceutical Form Characteristics | References | | |
|---------------------|------------------|--|--|-----------------|---|---------|
| LIQUID PREPARATIONS | ORAL SOLUTIONS | Example 5: Ozalin | Citric acid monohydrate, Gamma-cyclodextrin, Sucralose, Orange flavour (contains 70–80% ethanol), Sodium hydroxide, injectable water | Midazolam | | |
| | | Example 6: Flumil 20 mg/mL Oral Solution | Para-Hydroxybenzoate Methyl (E218), Sodium Benzoate (E211), Sodium Edetate, Carmellose Sodium, Sodium saccharine, Sodium Cyclamate, Sucralose, Raspberry Aroma, Sodium Hydroxide and Purified Water | Acetyl cysteine | See “Pharmaceutical Form Characteristics (Oral Solutions)” section of the previous page | [73–75] |
| | | Example 7: Paediatric Lanacordin 0.05 mg/mL <i>* Including newborns and premature</i> | Sucrose, Ethanol, Tartrazine (E-102), Anhydrous Sodium Phosphate, Citric Acid (E-330), Methyl Hydroxybenzoate, Lime Essential Oil, Propylene glycol (E-1520) and Purified Water | Digoxin | | |
| LIQUID PREPARATIONS | ORAL SUSPENSIONS | Example 1: Paracetamol 120 mg/5 mL Oral Suspension | Propylene glycol, Methyl Hydroxybenzoate, Propyl Hydroxybenzoate, Xanthan Gum, 70% Sorbitol Solution, Sucrose, Mango flavour and Purified Water | Paracetamol | As advantages, the following stand out: - Suspensions are the ideal pharmaceutical forms for the administration of non-water-soluble active ingredients. - The fact that the active substance is insoluble, allows an extension of the time of action in the body. - It is easier to mask the taste than in syrups and elixirs (more pleasant for children). - Good relative bioavailability. | [76,77] |
| | | Example 2: Junior Parapaed 120 mg/5 mL Oral Suspension | Ethanol, Polysorbate 80, Glycerol, Magnesium and Aluminium silicate, Liquid maltitol syrup, Sodium saccharine (E954), xanthan gum, cherry flavour, sodium benzoate, Citric acid monohydrate and purified water | Paracetamol | | |

Table A3. Cont.

| Pharmaceutical Form | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------|--|---|--|------------|
| LIQUID PREPARATIONS | <p>Example 3: Mycostatin 100.000 UI/mL Oral Suspension</p> | Nystatin | <p>Disadvantages include:</p> <ul style="list-style-type: none"> - Sediment formation. - Difficulty removing the viscosity of the vehicle. - Less stability than solid shapes, solutions and emulsions. - The use of very fine particle size causes the formation of sediments that are very difficult to re-suspend. <p><i>It is important to shake the suspension for at least 10 s before use</i></p> | [78,79] |
| | <p>Example 4: Paediatric Algidrin 20 mg/mL Oral Suspension * Do not give to children under 3 months of age</p> | | | |
| LIQUID PREPARATIONS | <p>Example 5: Paediatric Septrin 8 mg/40 mg/mL Oral Suspension * Suitable for infants from 6 weeks of age</p> | <ul style="list-style-type: none"> - Trimetho-prim - Sulfamethoxazole | <p>See "Pharmaceutical Form Characteristics (Oral Suspension)" section of the previous page</p> | [80] |

Table A3. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------|---------|--|-------------|--|------------|
| LIQUID PREPARATIONS | ELIXIRS | Example 1: Paracetamol Elixir Pediátrico 120 mg/5 mL | Paracetamol | - Hydro alcoholic solution sweetened with low sugar. - It has high alcohol content, which will have to be considered at certain ages, as it can create addition or generate other side effects: drowsiness and various dangers arising. | [29,81,82] |
| | | Example 2: Lanoxin Elixir <i>* Fit for premature neonates</i> | Digoxin | | |
| | SYRUPS | Example 1: Daleron Syrup 120 mg/5 mL | Paracetamol | - Syrups are liquid solutions with sweetening, flavouring and viscosizing properties. They are almost saturated aqueous solutions of sucrose (64%). They have the following drawbacks: | [29,83,84] |
| | | Example 2: Loratadine 5 mg/mL Syrup Oral Solution | Loratadine | - Alterations that require the incorporation of preservatives and specify | |

Table A3. Cont.

| Pharmaceutical Form | Excipients | API | Pharmaceutical Form Characteristics | References | | |
|-------------------------|------------------------------|---|---|-------------------------------|--|---------|
| LIQUID PREPARA-TIONS | SYRUPS | <p>Example 3: Polaramine 0.4 mg/mL Syrup <i>* Not suitable for children under 2 years old</i></p> | Ethanol, Sucrose, Sodium Citrate, Sodium Chloride, Sorbitol, Methyl paraben, Propyl paraben, Menthol, Apricot flavour, Orange flavour, Ponceau 4R Colouring (E-124) and Purified Water | Dexchlorpheni-ramine maleate | See “Pharmaceutical Form Characteristics (Syrups)” section of the previous page | [85,86] |
| | | <p>Example 4: Paediatric Mucosan 3 mg/mL Syrup</p> | Hydroxyethyl cellulose, Sucralose, Benzoic Acid (E-210), Wild Berry Aroma, Vanilla Aroma and Purified Water | Ambroxol hydrochloride | | |
| LIQUID PREPARATIONS | ORAL DROPS IN SOLUTION | <p>Example 1: Romillary 15 mg/mL Oral drops in Solution <i>* Not recommended for use in children under 2 years of age</i></p> | Propylene glycol, anhydrous ethanol, Flavourings: coriander oil, orange essential oil and lemon tetraroma, macrogol glycerol ricinolate (chromophore EL), Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, sodium saccharine, citric acid monohydrate, sodium hydroxide and purified water | Hydrobromide dextromethorphan | <ul style="list-style-type: none"> - Oral liquid medicinal products may be placed on the market in the form of drops for children of different ages. - The main benefits of drops are low dosing volume, facilitating swallowing and dosing flexibility. | [87–90] |
| | | <p>Example 2: Alerlisin 10 mg/mL Oral Drops in Solution <i>* Do not use in children under 2 years of age</i></p> | Glycerol, Propylene glycol (E-1520), Sodium Saccharine, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Sodium Acetate, Glacial Acetic Acid and Purified Water | Cetirizine hydrochloride | As disadvantages, the following stand out: the variation of the droplet size and errors in the count, which would result in an incorrect dosage. This can cause serious problems in those medicines with a narrow therapeutic margin. | |

Table A3. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------|-------------------------|--|---|--|--|
| LIQUIDPREPARA-TIONS | ORAL DROPS IN SOLUTION | Example 3: Paediatric Cleboril 62.5 g Oral Drops in Solution | Benzoic acid (E-210), Sodium hydroxide and purified water | Clebopride malate | See “Pharmaceutical Form Characteristics (Oral Drops in Solution)” section of the previous page [91–93] |
| | | Example 4: Fluor Lacer 1.4 mg/mL Oral Drops * Indicated for tooth decay prophylaxis in children 1–6 years old | Sodium Saccharine, Propylene glycol, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Disodium edetate, Cochineal Red Colouring (E-124), Strawberry Aroma and Purified Water | Sodium Fluoride | |
| | | Example 5: Hydropolivit Oral Drops in Solution * Recommended for children over 2 years old | Propylene glycol, Polysorbate 80, Sorbitol 70% (E-420), Glycerol (E-422), Sodium Saccharine, Sodium Edetate, Monothioglycerol, Methyl para hydroxybenzoate, Butylhydroxyanisole (E-320), Banana Essence, Vanilla Essence, Sodium Hydroxide and Purified Water | -Retinol palmitate Cholecalciferol Alpha-tocopherol acetate Riboflavin Pyridoxine hydrochloride Ascorbic acid Biotin Nicotinamide | |
| LIQUID PREPARATIONS | ORAL DROPS INSUSPENSION | Example 1: Zamene 22.75 mg/mL Oral Drops in Suspension * Special interest in paediatrics. Not recommended in children under 2 months of age. | Aluminium and Magnesium silicate, Carboxymethylcellulose sodium, Benzyl alcohol, 70% Sorbitol, Polysorbate 80, Acetic Acid and Purified Water | Deflazacort | They have the same characteristics as oral drops in solution [94,95] |

Table A3. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|--------------------------------|-------------|--|---|-------------------------------------|--|
| | | Example 2: Dezacor 22.75 mg/mL Oral Drops in Suspension * Special interest in paediatrics. Not recommended in children under 2 months of age. | Sorbitol solution 70%, Carboxymethylcellulose sodium, Aluminium silicate and magnesium, Polysorbate 80, Benzyl Alcohol, Sucralose, Tropical Fruit Aroma, Citric Acid Monohydrate, Sodium Hydroxide and Purified Water | Deflazacort | |
| OPHTHALMIC DROPS OR COLLYRIUMS | | Example 1: Atropine BP 1.0% (w/v)/Vistatropin 1.0% (w/v) Eye drops in solution | Benzalkonium chloride in solution and purified water | Atropine sulphate | - Sterile solutions aimed at exercising their action in the conjunctiva. |
| | | Example 2: Chibroxin 3 mg/mL Collyrium in solution | Sodium Acetate, Benzalkonium Chloride, Disodium Edetate, Concentrated Hydrochloric Acid, Sodium Chloride and Water for Injections | Norfloxacin | - May cause systemic side effects, especially observed after instillation of mydriatic eye drops. |
| LIQUID PREPARATIONS | NASAL DROPS | Example 1: Rhinovin® Children's 0.5 mg/mL Nasal Drops in Solution * Do not use in children under 6 years of age | Dihydrogen phosphate of sodium dihydrate, disodium phosphate dodecahydrate, disodium Edetate, Benzalkonium Chloride, Sorbitol (E420), Hypromellose, Sodium Chloride and Purified Water | Xylometazoline hydrochloride | - Aqueous solutions of medicinal substances that are instilled through the nose and act on the nasal mucosa. - Oils are contraindicated in their formulation, because the ciliary function has to be maintained. - It can be an excellent route of systemic administration, in addition to use as a topical route (there are promising studies with insulin and other substances). |

[29,68,96,97]

[29,68,98,99]

Table A3. Cont.

| Pharmaceutical Form | | Excipients | API | Pharmaceutical Form Characteristics | References |
|---------------------------------------|-------------|---|---|--|--|
| | | Example 2: Utabon Children 0.25 mg/mL Nasal Drops in Solution <i>* Do not use in children under 6 years of age</i> | Benzalkonium chloride, anhydrous disodium hydrogen phosphate, Sodium dihydrogen phosphate dihydrate, glycine (E-640), Sorbitol (E-420) and Purified water | Oxymetazoline hydrochloride | |
| | OTIC DROPS | Example 1: Otic cetraxal 3 mg/mL Otic drops en Solución <i>* Indicated in adults and child</i> | Lactic acid, Povidone, Anhydrous Glucose, Propylene glycol, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Hydrochloric Acid and Purified Water | Ciprofloxacin | - Liquid preparations to apply to the middle and outer ear. - The active substances are usually antiseptics, local anaesthetics and antibiotics. [29,100,101] |
| | | Example 2: Otix Otic Drops in Solution <i>* Do not administer in children under 2 years of age</i> | Benzalkonium Chloride, Sulphuric acid, Sodium Chloride, Sodium Hydroxide, Tribasic Sodium Citrate, Polysorbate 80, Citric Acid and Purified Water | - Dexamethasone sodium phosphate - Trimethoprim - Polymyxin B sulphate | Excipients have to be suitable to achieve a pH of 5–6. |
| LIQUID PREPARATIONS | OTIC DROPS | Example 3: Ciproxin Simple 3 mg/mL Otic Drops in Solution <i>* Not recommended for children under 1 year old</i> | Benzalkonium Chloride, Sodium Acetate Trihydrate, Glacial Acetic Acid, Mannitol (E-421), Disodium Edetate, Hydrochloric Acid and/or Sodium Hydroxide and Purified Water | Ciprofloxacin hydrochloride | See “Pharmaceutical Form Characteristics (Otic Drops)” section of the previous page [102] |
| PARENTERAL PREPARATIONS FOR INJECTION | INTRAVENOUS | Example 1: Digoxin Kern Pharma 0.25 mg/mL solution for injection <i>* including premature neonates</i> | Ethanol, Propylene Glycol, Citric Acid Anhydrous, Bi-sodium Anhydrous Phosphate and Bi-distillate Water. | Digoxin | - The intravenous line is the one of choice in new-borns and in emergencies. It achieves a quick effect and are easy to dos. - Risk of infection and can be painful at times and cause difficult-to-resolve injuries. [29,103] |

Appendix E

Table A4. Examples of FDA-registered drugs used in paediatrics (FDA and DAILYMED database consultation October 2020).

| Pharmaceutical Form | | Excipients | Active Principle | Age | References | | |
|---------------------|----------------|--|---|--|--|-----------------------|-------|
| LIQUID PREPARATIONS | ORAL SOLUTIONS | Abilify Solution Oral | Disodium edetate, fructose (200 mg per mL), glycerine, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose (400 mg per mL), and purified water. The Oral solution is flavoured with natural orange cream and other natural flavours | Aripiprazole | 6 to 18 years | [104] | |
| | | Demerol Solution Oral | Benzoic acid, flavour, liquid glucose, purified water, saccharin sodium | Meperidine hydrochloride | Adult and paediatric patients | [105] | |
| | | Diazepam Oral Solution (Lannett Company) | Polyethylene glycol, propylene glycol, non-crystallizing sorbitol solution, sodium citrate anhydrous, bitterness modifier flavour, anhydrous citric acid, peppermint flavour, mint flavour, FD&C Network No. 40 aluminium lake, D&C Yellow No. 10 aluminium lake and purified water | Diazepam (5 mg/5 mL) | Children from 6 months | [106] | |
| | | ORAL SUSPENSIONS | Adzenys ER (Extend release) | Purified water, sorbitol, propylene glycol, xanthan gum, natural orange flavour, methacrylic acid and methyl methacrylate copolymer, sodium polystyrene sulfonate, vegetable oil, triethyl citrate, methylparaben, citric acid, sucralose, propylparaben, orange colour (FD&C Yellow No. 6), and polyethylene glycol | Amphetamine | 6 to 17 years | [107] |
| | | | Children's Tylenol® Cold + Cough + Sore Throat Oral Suspension | Anhydrous citric acid, D&C network No. 33, FD&C network No. 40, flavours, glycerine, microcrystalline cellulose and sodium carboxymethyl cellulose, purified water, sodium benzoate, sorbitol solution, sucralose, xanthan gum | Acetaminophen 160 mg Dextromethorphan hydrobromide 5 mg | 4 to 11 years | [108] |
| | | ORAL SUSPENSIONS | Dyanavel XR (Extend release) | Anhydrous citric acid, bubble-gum flavour, glycerine, methylparaben, modified food starch, polysorbate 80, povidone, polyvinyl acetate, propylparaben, sodium lauryl sulphate, sodium polystyrene sulfonate, sucralose, triacetin and xanthan gum | Amphetamine | Children from 6 years | [109] |
| | SYRUPS | Midazolam hydrochloride syrup | Anhydrous Citric Acid, D&C Network No. 33, edetate disodium, glycerine, sodium benzoate, sorbitol, Water, Hydrochloric Acid, Sodium Citrate | Midazolam hydrochloride | Children from 6 months | [110] | |

Table A4. Cont.

| Pharmaceutical Form | | Excipients | Active Principle | Age | References | |
|---------------------|--|---|---|--|--|-------|
| LIQUID PREPARATIONS | OTIC DROPS | Ciprofloxacin and dexamethasone suspension/drops | Benzalkonium chloride, boric acid, edetate disodium, acetic acid, sodium acetate, sodium chloride, sodium hydroxide, tyloxapol, water, hydrochloric acid, hydroxyethyl cellulose (3000 cps at 1%) | - Ciprofloxacin hydrochloride - Dexamethasone | Children from 6 months | [111] |
| | OPHTHALMIC DROPS OR COLLYRIUMS | ALLERGY EYE DROPS-ketotifen fumarate solution/drops | Benzalkonium chloride 0.01%, glycerine, purified water. may contain hydrochloric acid and/or sodium hydroxide (to adjust PH). | Ketotifen (0.025 %) (equivalent to ketotifen fumarate 0.035 %) | Children from 3 years. Children under 3 years of age: consult to doctor | [112] |
| | NASAL DROPS | LITTLE REMEDIES DECONGESTANT NASAL DROPS phenylephrine hydrochloride liquid | Benzalkonium chloride, glycerine, polyethylene glycol, potassium phosphate monobasic, purified water, Sodium EDTA, sodium phosphate dibasic | Phenylephrine hydrochloride 1.25 mg/mL | Children | [113] |
| ORAL DROPS | BIO-G-TUSS PAEDIATRIC DROPS (solution) | Citric acid, grape flavour, glycerine, methylparaben, polyethylene glycol, propylparaben, purified water, Sodium citrate, sucralose | - Dextromethorphan HBr (7.5 mg/mL) - Guaifenesin (88 mg/mL) - Phenylephrine HCl (2.5 mg/mL) | Children | [114] | |
| SOLI PREPARATIONS | CHEWABLE TABLET | Children's Motrin—Ibuprofen Tablet, Chewable | Acesulfame potassium, ammonium glycyrrhizin, aspartame, carnauba wax, croscarmellose sodium, hypromellose, magnesium stearate, mannitol, natural and artificial flavours, silicon dioxide, sodium lauryl sulphate, soybean oil, succinic acid | Ibuprofen 100 mg | 2 to 11 years | [115] |
| | | Acetaminophen Children's | Citric acid, crospovidone, D&C network No. 27 aluminium lake, D&C network No. 30 aluminium lake, dextrates hydrated, ethyl cellulose, flavours, magnesium stearate, mannitol, polyethylene, stearic acid, sucralose | Acetaminophen 80 mg | 2 to 6 years | [116] |
| | TABLETS | Diazepam Tablet | Anhydrous lactose, magnesium stearate, cellulose microcrystalline, FD&C blue n. 1 | Diazepam 10 mg | Children from 6 months | [117] |
| | | Dexamethasone 1.5 mg tablet | Lactose monohydrate, magnesium stearate, maltodextrin, corn starch, sucrose | Dexamethasone 1.5 mg | It depends on the pathology | [118] |

Appendix F

Table A5. Liquid formulations for paediatric use in Research Articles.

| Formula | Pharmaceutical Form | Excipients | Active Principle (Dose) | Age | Stability (Stability in Use) | References |
|--|--------------------------------|--|---|--|--|------------|
| Organic solvent-based formulation of lorazepam (Oral Solution) | Oral solution | PEG 400 (10% <i>v/v</i>), Propylene glycol (3% <i>m/v</i>), Glycerol (87% <i>v/v</i>) and Orange essence (0.1%) | Lorazepam (1 mg/mL) | Children 1 month to 12 years old | 12 months at 4 °C (Stability in use: 4 weeks) | [119] |
| Oral solution of amlodipine besylate for children | Oral solution | Sucrose jarabe (32% <i>m/v</i>), Methylparaben (solution 15% <i>m/v</i>) (0.3% <i>m/v</i>) and Purified water (75%) | Amlodipine Besylate (0.5 mg/mL) | Paediatric Population (children and teenagers) | 12 months at 4 °C (Stability in use: 18 weeks) | [120] |
| Oral tizanidine hydrochloride, Formulation for hospital use | Oral solution | CMC (carboxymethyl cellulose) (0.5%), Potassic sorbate (0.15%), Sucralose (0.10%), Citric acid and Purified water | Tizanidine Hydrochloride (1 g/mL) | Paediatric Population | 70 days at 15–30 °C, 2–8 °C and 40 °C | [121] |
| Paediatric oral formulation of clonidine hydrochloride | Oral solution | Sucrose syrup (20% <i>v/v</i>), Raspberry essence (0.05%), Methyl paraben solution 15% (1% <i>m/v</i>), Citric acid monohydrate (1% <i>m/v</i>), Disodium hydrogen phosphate (1.8% <i>m/v</i>) and Purified water | Clonidine HCL (50 µg/mL) | Paediatric Population | 9 months at room temperature, protected from light | [122] |
| Oral liquid formulation of clonidine hydrochloride for paediatric patients | Oral solution | Potassic sorbate, Sucrose and Monohydrate citric acid | Clonidine hydrochloride (20 µg/mL) | Paediatric Patients (all ages) | 90 days at 5 °C (cooling) (Stability in use: 42 days at 5 °C) | [123] |
| Paediatric oral formulations of sodium dichloroacetate | Oral solution | Vehicle Mascagni (% <i>w/v</i>): Sucralose (0.02%), Hydroxyethyl cellulose (0.2%), Citric acid (0.09%), Sodium citrate (0.09%) and Potassium sorbate (0.18%) | Sodium dichloroacetate (DCA) (9.5% <i>w/v</i>) | Paediatric Patients | 3 months at 4 °C and 25 °C (Stability in use: 1 month to 4 °C) | [124] |
| Furosemide solutions for personalized paediatric administration | Oral solution (extemporaneous) | Solution I: Buffer carbonate-bicarbonate (pH) (10 mL) Excipient for syrup (cps 100 mL) (ACOFARMA): sucrose, water, sorbitol, glycerine, aroma, citric acid, methyl paraben, potassium sorbate, sodium phosphate and colorant. Solution II: Buffer carbonate-bicarbonate (pH) (10 mL) -Excipient for syrup—without sugars (cps 100 mL) (ACOFARMA): sodium saccharine, xanthan gum, water, sorbitol, glycerine, aroma, citric acid, sodium citrate, methyl paraben, propyl paraben, potassium sorbate, sodium phosphate and colorant. | Furosemide (2 mg/mL) | Paediatrics | 60 days at 4 and 25 °C | [125] |
| Formulation comprising acetaminophen, especially for paediatrics (PATENT) | Oral solution (nano-emulsion) | NF glyceryl mono linoleate (5–30%, preferably 8–26% <i>w/v</i>), PEG-35 castor oil (30–60%, preferably 39–46% <i>w/v</i>), NF diethylene glycol mono ethyl ether (20–45%, preferably 24–40% <i>w/v</i>) and Water | Paracetamol (5–18% <i>w/v</i>) | Paediatrics | NA | [126] |

Table A5. Cont.

| Formula | Pharmaceutical Form | Excipients | Active Principle (Dose) | Age | Stability (Stability in Use) | References |
|---|---------------------|---|---|----------------------------------|---|------------|
| Paediatric formulations of ursodeoxycholic acid from oral administration | Oral suspension | Glycerol (20%), Methyl cellulose 1000 (1% <i>v/v</i>) and Purified water | Ursodeoxycholic acid (UDCA) (1.5 mg/mL) | Paediatric Population | 30 days at 25 °C or in fridge | [127] |
| Oral paediatric formulation of hydrochlorothiazide | Oral suspension | Glycerol (20%), Methyl cellulose 1000 (1% <i>v/v</i>), Citric acid (pH corrector) and Water | Hydrochlorothiazide (2 mg/mL) | Paediatric Population in general | 3 weeks at 5 °C and protected from light | [128] |
| Oral suspension of clindamycin HCL with ion exchange resin for paediatric use | Oral suspension | Glycerine (30% <i>w/v</i>), Sucralose (3%), Aroma of maple syrup (7%), Grape aroma (10%), Cremophor RH 40 (15%), Xanthan gum (0.2%) and Deionized water (cps 5 mL) | Clindamycin HCL resin (Amberlite IRP 69) (5.5% <i>w/v</i>) | Paediatric Population | 1 month at 25 °C | [129,130] |
| Isoniazid suspension formulated with cationic resin for paediatric use | Oral suspension | Sorbitol solution 70% USP (4.9 mL/ 5 mL), USP monohydrate citric acid (50 mg/5 mL) and USP potassic sorbate (5 mg/5 mL) | Isoniazid resin/Kyron T-134 100 mg/5 mL/200 mg/5 mL | Paediatric Population | 3 months at 40 °C (accelerated stability study) | [131] |
| Paediatric xylometazoline nasal spray formulation | Nasal Spray | Sodium colatum (105 mg/10 mL), PEG 400 (1.35 mL/10 mL), Sodium carboxy methyl cellulose (10 mg/10 mL), Glycerine (0.15 mL/10 mL), Methyl paraben (3.3 mg/10 mL), Sodium chloride and Purified water (cps 10 mL) | Xylometazoline HCl (5 mg/10 mL) | Paediatric Population | 12 months at 25 °C | [132] |

References

1. Cañete, C.R.; García, M.P.; García, B.P.; Cabañas, M.J.P. Formulación magistral y excipientes en pediatría. *El Farmacéutico. Hospitales* **2018**, *213*, 22–28.
2. Salunke, S.; Brandys, B.; Giacoia, G.; Tuleu, C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: Part 2—The pilot version. *Int. J. Pharm.* **2013**, *457*, 310–322. [[CrossRef](#)] [[PubMed](#)]
3. Schmitt, G. Safety of Excipients in Pediatric Formulations—A Call for Toxicity Studies in Juvenile Animals? *Child* **2015**, *2*, 191–197. [[CrossRef](#)] [[PubMed](#)]
4. European Medicines Agency (EMA); Committee for Medicinal Products for Human Use (CHMP); Paediatric Committee (PDCO). Guideline on Pharmaceutical Development of Medicines for Paediatric Use. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf (accessed on 1 June 2020).
5. Dunne, J. The European Regulation on medicines for paediatric use. *Paediatr. Respir. Rev.* **2007**, *8*, 177–183. [[CrossRef](#)]
6. European Medicines Agency. European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Available online: <https://www.ema.europa.eu/en/partners-networks/networks/european-network-paediatric-research-european-medicines-agency-enpr-ema> (accessed on 1 June 2020).
7. EUR-Lex. Regulation EC No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Available online: <https://eur-lex.europa.eu/eli/reg/2006/1901/oj> (accessed on 1 July 2020).
8. European Medicines Agency. 10-Year Report to the European Commission. Available online: https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf (accessed on 2 June 2020).
9. European Medicines Agency. ICH E11(R1) Guideline on Clinical Investigation of Medicinal Products in the Pediatric Population. Step 5 [Internet]. Available online: <https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population> (accessed on 2 June 2020).
10. Turner, M.; Catapano, M.; Hirschfeld, S.; Giaquinto, C. Paediatric drug development: The impact of evolving regulations. *Adv. Drug Deliv. Rev.* **2014**, *73*, 2–13. [[CrossRef](#)] [[PubMed](#)]
11. WHO Library Cataloguing-in-Publication Data: WHO Model Formulary for Children 2010. Based on the Second Model List of Essential Medicines for Children 2009. Available online: <http://www.who.int/bookorders> (accessed on 5 June 2020).
12. WHO World Health Organization. Model List of Essential Medicines for Children. Available online: <https://apps.who.int/iris/bitstream/handle/10665/325772/WHO-MVP-EMP-IAU-2019.07-eng.pdf> (accessed on 6 June 2020).
13. Daousani, C.; Karalis, V.D. Paediatric Medicines: Regulatory and Scientific Issues. *Drug Res.* **2017**, *67*, 377–384. [[CrossRef](#)] [[PubMed](#)]
14. FDA, Alyson Karesh MD. Pediatric Drug Development: Regulatory Expectations. Available online: <https://www.fda.gov/files/drugs/published/Pediatric-Drug-Development--Regulatory-Expectations.pdf> (accessed on 7 June 2020).
15. FDA. Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. Available online: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients> (accessed on 7 June 2020).
16. Walsh, J.; Mills, S. Conference Report: Formulating Better Medicines for Children: 4th European Paediatric Formulation Initiative Conference. *Ther. Deliv.* **2013**, *4*, 21–25. [[CrossRef](#)] [[PubMed](#)]
17. Christiansen, N. Ethanol exposure through medicines commonly used in paediatrics. *Arch. Dis. Child. Educ. Pract.* **2014**, *100*, 101–104. [[CrossRef](#)]
18. Tuleu, C.; Breikreutz, J. Educational Paper: Formulation-related issues in pediatric clinical pharmacology. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *172*, 717–720. [[CrossRef](#)]
19. Salunke, S.; Liu, F.; Batchelor, H.; Walsh, J.; Turner, R.; Ju, T.R.; Tuleu, C.; on behalf of European Paediatric Formulation Initiative (EuPFI). European Paediatric Formulation Initiative (EuPFI)—Formulating Ideas for Better Medicines for Children. *AAPS PharmSciTech* **2016**, *18*, 257–262. [[CrossRef](#)]
20. Salunke, S. Development and Evaluation of Database of Safety and Toxicity of Excipients for Paediatrics (STEP Database). Ph.D. Thesis, University College London, London, UK, 2017. Available online: <https://discovery.ucl.ac.uk/id/eprint/1546094/> (accessed on 20 July 2020).
21. Salunke, S.; Tuleu, C. The STEP database through the end-users eyes—USABILITY STUDY. *Int. J. Pharm.* **2015**, *492*, 316–331. [[CrossRef](#)] [[PubMed](#)]
22. Salunke, S.; Giacoia, G.; Tuleu, C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1—A need assessment study. *Int. J. Pharm.* **2012**, *435*, 101–111. [[CrossRef](#)] [[PubMed](#)]
23. Fonger, G.C.; Hakkinen, P.; Jordan, S.; Publicker, S. The National Library of Medicine’s (NLM) Hazardous Substances Data Bank (HSDB): Background, recent enhancements and future plans. *Toxicology* **2014**, *325*, 209–216. [[CrossRef](#)] [[PubMed](#)]
24. Valeur, K.S.; Hertel, S.A.; Lundstrøm, K.E.; Holst, H. Safe excipient exposure in neonates and small children—Protocol for the SEEN project. *Dan Med. J.* **2017**, *64*, A5324.

25. Fabiano, V.; Mamelì, C.; Zuccotti, G.V. Paediatric pharmacology: Remember the excipients. *Pharmacol. Res.* **2011**, *63*, 362–365. [CrossRef] [PubMed]
26. Soremekun, R.; Ogbuefi, I.; Aderemi-Williams, R. Prevalence of ethanol and other potentially harmful excipients in pediatric oral medicines: Survey of community pharmacies in a Nigerian City. *BMC Res. Notes* **2019**, *12*, 1–5. [CrossRef]
27. Buckley, L.A.; Salunke, S.; Thompson, K.; Baer, G.; Fegley, D.; Turner, M.A. Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients. *Int. J. Pharm.* **2018**, *536*, 563–569. [CrossRef]
28. Parneli, C.; Srivari, Y.; Meiki, Y.; Mohammed, A.; Sri, V. Pharmaceutical excipients and paediatric formulations. *Chem. Today* **2012**, *30*, 56–61.
29. Peiré, M.A.G. *Farmacología Pediátrica*, 1st ed.; Ediciones Journal: Ciudad Autónoma de Buenos Aires, Argentina, 2019.
30. Rowe, R.C.; Sheskey, P.J.; Owen, S.C. *Handbook of Pharmaceutical Excipients*, 6th ed.; Pharmaceutical Press: London, UK, 2006.
31. Zuccotti, G.V.; Fabiano, V. Safety issues with ethanol as an excipient in drugs intended for pediatric use. *Expert Opin. Drug Saf.* **2011**, *10*, 499–502. [CrossRef] [PubMed]
32. European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP). Questions and Answers on Ethanol in the Context of the Revision of the Guideline on 'Excipients in the Label and Package Leaflet of Medical Products for Human Use' (CPMP/463/00). Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-ethanol-context-revision-guideline-excipients-label-package-leaflet-medicinal_en.pdf (accessed on 10 March 2020).
33. Allegaert, K. Propylene Glycol in Neonates: Never Prescribed, Frequently Administered, Hardly Evaluated. *J. Clin. Toxicol.* **2012**, *2*, 113. [CrossRef]
34. Allegaert, K.; Vanhaesebrouck, S.; Kulo, A.; Cosaert, K.; Verbesselt, R.; Debeer, A.; De Hoon, J. Prospective assessment of short-term propylene glycol tolerance in neonates. *Arch. Dis. Child.* **2010**, *95*, 1054–1058. [CrossRef]
35. Hidalgo, M.E.P.; Sánchez, B.N. Formas Farmacéuticas Líquidas Orales (II): Excipientes. *Panor. Actual Medicam.* **2016**, *40*, 842–848. Available online: <https://dialnet.unirioja.es/servlet/articulo?codigo=5685059> (accessed on 20 May 2020).
36. Nellis, G.; Metsvaht, T.; Varendi, H.; Toompere, K.; Lass, J.; Mesek, I.; Nunn, A.J.; A Turner, M.; Lutsar, I. Potentially harmful excipients in neonatal medicines: A pan-European observational study. *Arch. Dis. Child.* **2015**, *100*, 694–699. [CrossRef]
37. Nellis, G. The Use of Excipients in Medicines Administered to Neonates in Europe. Ph.D. Thesis, University of Tartu, Tartu, Estonia, 2017. Available online: <http://rahvatervis.ut.ee/handle/1/6757> (accessed on 3 May 2020).
38. Graham, S.; Turner, M. European Study of Neonatal Exposure to Excipients (ESNEE). *Infant* **2011**, *7*, 196–199. Available online: http://www.infantjournal.co.uk/pdf/inf_042_ien.pdf (accessed on 3 May 2020).
39. Nahata, M.C. Safety of "inert" additives or excipients in paediatric medicines. *Arch. Dis. Child. Fetal Neonatal Ed.* **2009**, *94*, F392–F393. [CrossRef]
40. Whittaker, A.; Currie, A.E.; Turner, M.A.; Field, D.J.; Mulla, H.; Pandya, H.C. Toxic additives in medication for pre-term infants. *Arch. Dis. Child. Fetal Neonatal Ed.* **2009**, *94*, 236–240. Available online: <https://fn.bmj.com/content/94/4/F236> (accessed on 20 May 2020). [CrossRef]
41. Committee on Drugs "Inactive" Ingredients in Pharmaceutical Products: Update (Subject Review). *Pediatrics* **1997**, *99*, 268–278. [CrossRef] [PubMed]
42. Fister, P.; Urh, S.; Karner, A.; Krzan, M.; Paro-Panjan, D. The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia. *J. Matern. Neonatal Med.* **2015**, *28*, 2053–2061. [CrossRef] [PubMed]
43. Committee for Medicinal Products for Human Use (CHMP). Reflection Paper: Formulations of Choice for the Paediatric Population Agreed by Paediatric Working Party & Quality Working Party Adoption by Chmp for Release for Consultation End of Consultation (Deadline for Comments). Available online: <https://www.ema.europa.eu/en/formulations-choice-paediatric-population> (accessed on 20 March 2020).
44. Valeur, K.S.; Holst, H.; Allegaert, K. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. *Pharm. Med.* **2018**, *32*, 251–258. [CrossRef] [PubMed]
45. Faulí, T.C. *Tratado de Farmacia Galénica.*, 1st ed.; Luzán 5, S.A. de Ediciones: Madrid, Spain, 1993.
46. Vally, H.; La Misso, N. Adverse reactions to the sulphite additives. *Gastroenterol. Hepatol. Bed Bench* **2012**, *5*, 16–23.
47. Duro, D.; Rising, R.; Cedillo, M.; Lifshitz, F. Association between infantile colic and carbohydrate malabsorption from fruit juices in infancy. *Pediatrics* **2002**, *109*, 797–805. [CrossRef]
48. Nakama, K.; Dos Santos, R.; Serpa, P.; Maciel, T.; Haas, S. Organoleptic excipients used in pediatric antibiotics. *Arch. Pédiatrie* **2019**, *26*, 431–436. [CrossRef]
49. Punín, E.C.; Ballester, A.V.; Dávila, C.P.; Varela, J.J.C.; López, M.J.O.; Arias, J.D.; Segado, M.I.J.; Herrero, L.P.; Fortes, S.G.; Piñeiro, G.C.; et al. *Aspectos Prácticos de la Farmacotecnia en un Servicio de Farmacia. Situación Actual [Online]*; Piñeiro, G.C., Ed.; Master Line & Prodigio S.L.: Madrid, Spain, 2011. Available online: www.sefh.es/bibliotecavirtual/FARMACOTECNIA/AspectosPracticos.pdf (accessed on 13 October 2020).
50. Euskadi.eus. Boletín INFAC. Año 2019. Volumen 27. N° 3- Excipientes: ¿Sustancias Inertes? Available online: <https://www.euskadi.eus/boletin-infac-ano-2019-volumen-27/web01-a2cevime/es/> (accessed on 13 October 2020).
51. Gryczke, A.; Schminke, S.; Maniruzzaman, M.; Beck, J.; Douroumis, D. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. *Colloids Surf. B Biointerfaces* **2011**, *86*, 275–284. [CrossRef] [PubMed]

52. Pahwa, R.; Piplani, M.; Sharma, P.C.; Kaushik, D.; Nanda, S. Orally Disintegrating Tablets—Friendly to Pediatrics and Geriatrics. *Arch. Appl. Sci. Res.* **2010**, *2*, 35–48. Available online: www.scholarsresearchlibrary.com/articles/orally-disintegrating-tablets-friendly-to-pediatrics-and-geriatrics.pdf (accessed on 14 November 2020).
53. Aguilar-Díaz, J.E.; García-Montoya, E.; Suñe-Negre, J.M.; Pérez-Lozano, P.; Miñarro, M.; Tico, J.R. Predicting orally disintegrating tablets formulations of ibuprofen tablets: An application of the new SeDeM-ODT expert system. *Eur. J. Pharm. Biopharm.* **2012**, *80*, 638–648. [CrossRef]
54. Arvapalli, S.; Swamy, D.; Shyamala. Oral Disintegration Tablets: An Updated Review. *IAJPS* **2019**, *6*, 6926–6934. [CrossRef]
55. Herrada-Manchón, H.; Rodríguez-González, D.; Fernández, M.A.; Suñe-Pou, M.; Pérez-Lozano, P.; García-Montoya, E.; Aguilar, E. 3D printed gummies: Personalized drug dosage in a safe and appealing way. *Int. J. Pharm.* **2020**, *587*, 119687. [CrossRef] [PubMed]
56. Kriegel, C.; Festag, M.; Kishore, R.S.; Roethlisberger, D.; Schmitt, G. Pediatric Safety of Polysorbates in Drug Formulations. *Children* **2019**, *7*, 1. [CrossRef]
57. AEMPS. CIMA. *Ficha Técnica Amoxicilina Normon 250 mg/5 mL Polvo para Suspensión Oral EFG*. Available online: https://cima.aemps.es/cima/dochtml/ft/63354/FT_63354.html (accessed on 1 July 2020).
58. AEMPS. CIMA. *Ficha Técnica Azitromicina Sandoz 200 mg/5 mL Polvo para Suspensión Oral EFG*. Available online: https://cima.aemps.es/cima/dochtml/ft/71180/FT_71180.html#6-datos-farmac-uticos (accessed on 1 July 2020).
59. AEMPS. CIMA. *Ficha Técnica Gelocatil Pediátrico 325 mg Granulado*. Available online: https://cima.aemps.es/cima/dochtml/ft/72343/FT_72343.html#6-datos-farmac-uticos (accessed on 1 July 2020).
60. AEMPS. CIMA. *Ficha Técnica Apiretal 325 mg Comprimidos Bucodispersables*. Available online: https://cima.aemps.es/cima/dochtml/ft/70571/FT_70571.html#6-datos-farmac-uticos (accessed on 1 July 2020).
61. AEMPS. CIMA. *Ficha Técnica Junifen 200 mg Comprimidos Bucodispersables Sabor Limón*. Available online: https://cima.aemps.es/cima/dochtml/ft/64966/FT_64966.html#6-datos-farmac-uticos (accessed on 5 July 2020).
62. AEMPS. CIMA. *Ficha Técnica Febrectal Lactantes 150 mg Supositorios*. Available online: https://cima.aemps.es/cima/dochtml/ft/45930/FT_45930.html#6-datos-farmac-uticos (accessed on 5 July 2020).
63. AEMPS. CIMA. *Ficha Técnica Fenistil 1 mg/g Gel*. Available online: https://cima.aemps.es/cima/dochtml/ft/54083/FT_54083.html (accessed on 9 July 2020).
64. AEMPS. CIMA. *Ficha Técnica Perme-Cure 5 % Crema*. Available online: https://cima.aemps.es/cima/pdfs/ft/64052/FT_64052.pdf (accessed on 9 July 2020).
65. AEMPS. CIMA. *Ficha Técnica Oftacilox 3 mg/g Pomada Oftálmica*. Available online: https://cima.aemps.es/cima/dochtml/ft/64904/FT_64904.html#1-nombre-del-medicamento (accessed on 9 July 2020).
66. AEMPS. CIMA. *Ficha Técnica Anticongestiva Cusi (Pasta Lassar)*. Available online: https://cima.aemps.es/cima/dochtml/ft/33302/FT_33302.html#6-datos-farmac-uticos (accessed on 9 July 2020).
67. AEMPS. CIMA. *Ficha Técnica Lactisona 10 mg/mL Emulsión Cutánea. Ficha Técnica*. Available online: https://cima.aemps.es/cima/dochtml/ft/59709/FichaTecnica_59709.html (accessed on 9 July 2020).
68. Eichholtz, F. *Tratado de Farmacología*, 1st ed.; Editorial Aguilar: Madrid, Spain, 1961.
69. ACCORD. Diazepam 2 mg/5 mL Oral Solution Sugar Free. *Package Leaflet: Information for the Patient*. Available online: <https://www.medicines.org.uk/emc/product/5783/pil> (accessed on 3 August 2020).
70. AEMPS. CIMA. *Ficha Técnica Paracetamol Level 100 mg/mL Solución Oral EFG*. Available online: https://cima.aemps.es/cima/dochtml/ft/68318/FT_68318.html (accessed on 3 August 2020).
71. RxList. Diazepam Intensol. Available online: https://www.rxlist.com/diazepam-intensol-drug.htm#side_effects (accessed on 3 August 2020).
72. Focus Pharmaceuticals Ltd. Prednisolone 10 mg/mL Oral Solution. *Package Leaflet: Information for the User*. Available online: <https://www.medicines.org.uk/emc/product/3370/smpc> (accessed on 3 August 2020).
73. PRIMEX PHARMACEUTICALS. Ozalin® 2 mg/mL. *Package Leaflet: Information for the User*. Available online: https://mri.cts-mrp.eu/Human/Downloads/FR_H_0610_001_FinalPL.pdf (accessed on 4 August 2020).
74. AEMPS. CIMA. *Ficha Técnica Flumil 20 mg/mL Solución Oral*. Available online: https://cima.aemps.es/cima/dochtml/ft/63512/FT_63512.html (accessed on 5 August 2020).
75. AEMPS. CIMA. *Ficha Técnica Lanacordin Pediátrico 0.05 mg/mL Solución Oral*. Available online: https://cima.aemps.es/cima/dochtml/ft/34755/FichaTecnica_34755.html (accessed on 5 August 2020).
76. Rosemont Pharmaceuticals Limited. Paracetamol 120 mg/5 mL Oral Suspension. *Package Leaflet: Information for the User*. Available online: <https://www.medicines.org.uk/emc/product/6693/smpc> (accessed on 7 August 2020).
77. Pinewood Laboratories Limited. Junior Parapaed 120 mg/5 mL Oral Suspension. *Patient Information Leaflet*. Available online: <https://www.hpra.ie/img/uploaded/swedocuments/bf1ca653-1934-4daa-8632-f76bef7c70c.pdf> (accessed on 7 August 2020).
78. AEMPS. CIMA. *Ficha Técnica Mycostatin 100,000 UI/mL Suspensión Oral*. Available online: https://cima.aemps.es/cima/dochtml/ft/28262/FichaTecnica_28262.html (accessed on 7 August 2020).
79. AEMPS. CIMA. *Ficha Técnica Algídrin Pediátrico 20 mg/mL Suspensión Oral*. Available online: https://cima.aemps.es/cima/dochtml/ft/78859/FichaTecnica_78859.html (accessed on 8 August 2020).
80. AEMPS. CIMA. *Ficha Técnica Septrin Pediátrico 8 mg/40 mg/mL Suspensión Oral*. Available online: https://cima.aemps.es/cima/pdfs/es/ft/48671/48671_ft.pdf (accessed on 8 August 2020).

81. Pinewood Laboratories Limited. Patient Information Leaflet: Paediatric Paracetamol Elixir BP Paracetamol 120 mg/5 mL. Available online: <https://www.drugs.com/uk/paediatric-paracetamol-elixir-bp-leaflet.html> (accessed on 9 August 2020).
82. Aspen Pharma. Lanoxin Pg Elixir. *Package Leaflet: Information for the User*. Available online: <https://www.medicines.org.uk/emc/product/5463/smpc> (accessed on 10 August 2020).
83. Medicine-Online. Daleron Syrup 120 mg/5 mL. 100 mL. Available online: <https://www.medicine-online.org/en/quality-products/2483-daleron-syrup-120-mg-5-ml-100-ml-.html> (accessed on 10 August 2020).
84. Pinewood Healthcare. Loratadine 5 mg/5 mL Syrup. *Patient Information Leaflet*. Available online: <https://www.medicines.org.uk/emc/product/4567/smpc> (accessed on 11 August 2020).
85. AEMPS. CIMA. *Ficha Técnica Polaramine 0.4 mg/mL Jarabe*. Available online: https://cima.aemps.es/cima/dohtml/ft/32801/FichaTecnica_32801.html (accessed on 11 August 2020).
86. AEMPS. CIMA. *Ficha Técnica Mucosan Pediátrico 3 mg/mL Jarabe*. Available online: https://cima.aemps.es/cima/dohtml/ft/56156/FT_56156.html (accessed on 11 August 2020).
87. AEMPS. CIMA. *Ficha Técnica Romilar 15 mg/mL Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/24379/FT_24379.html (accessed on 12 August 2020).
88. AEMPS. CIMA. *Ficha Técnica Alerlisin 10 mg/mL Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/62788/FT_62788.html (accessed on 12 August 2020).
89. AEMPS. CIMA. *Fiche Técnica Cleboril Pediátrico 62.5 µg Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/56657/FichaTecnica_56657.html (accessed on 12 August 2020).
90. AEMPS. CIMA. *Ficha Técnica Fluor Lacer 1.4 mg/mL Gotas Orales*. Available online: https://cima.aemps.es/cima/dohtml/ft/57746/FT_57746.html (accessed on 13 August 2020).
91. AEMPS. CIMA. *Fiche Técnica Hidropolivit Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/44000/FT_44000.html (accessed on 13 August 2020).
92. AEMPS. CIMA. *Fiche Técnica Largactil 40 mg/mL Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/23661/FichaTecnica_23661.html (accessed on 13 August 2020).
93. AEMPS. CIMA. *Ficha Técnica Nemaetil 40 mg/mL Gotas Orales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/41573/FT_41573.html (accessed on 14 August 2020).
94. AEMPS. CIMA. *Fiche Técnica Zamene 22.75 mg/mL Gotas Orales en Suspensión*. Available online: https://cima.aemps.es/cima/dohtml/ft/61050/FT_61050.html (accessed on 14 August 2020).
95. AEMPS. CIMA. *Fiche Técnica Dezacor 22.75 mg/mL Gotas Orales en Suspensión*. Available online: https://cima.aemps.es/cima/dohtml/ft/61049/FT_61049.html (accessed on 14 August 2020).
96. EMC (ELECTRONIC MEDICINES COMPENDIUM). Atropine Eye Drops BP 1.0% w/v Vistatropine Eye Drops 1.0% w/v. Available online: <https://www.medicines.org.uk/emc/medicine/29117> (accessed on 24 August 2020).
97. AEMPS. CIMA. *Fiche Técnica Chibroxin 3 mg/ml Colirio en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/59248/FichaTecnica_59248.html (accessed on 24 August 2020).
98. AEMPS. CIMA. *Fiche Técnica Rhinovin® Infantil 0.5 mg/mL Gotas Nasales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/37037/FT_37037.html (accessed on 24 August 2020).
99. AEMPS. CIMA. *Ficha Técnica Utabon Niños 0.25 mg/mL Gotas Nasales en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/46065/FT_46065.html (accessed on 25 August 2020).
100. AEMPS. CIMA. *Fiche Técnica Cetraxal Ótico 3 mg/mL Gotas Óticas en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/60883/FT_60883.html (accessed on 25 August 2020).
101. AEMPS. CIMA. *Fiche Técnica Otix Gotas Óticas en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/59381/FT_59381.html (accessed on 25 August 2020).
102. AEMPS. CIMA. *Fiche Técnica Ciproxina Simple 3 mg/L Gotas Óticas en Solución*. Available online: https://cima.aemps.es/cima/dohtml/ft/64940/FichaTecnica_64940.html (accessed on 25 August 2020).
103. AEMPS. CIMA. *Fiche Técnica Digoxina Kern Pharma 0.25 mg/mL Solución Inyectable*. Available online: https://cima.aemps.es/cima/dohtml/ft/34753/FT_34753.html (accessed on 25 August 2020).
104. FDA. Abilify Solution Oral. Medication Guide. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf (accessed on 10 October 2020).
105. FDA. Demerol Solution Oral. Medication Guide. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/005010s058lbl.pdf (accessed on 10 October 2020).
106. DAILYMED. DIAZEPAM SOLUTION, Lannett Company. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8cb8fe7-3744-41fa-8981-05a7fa8a2ec3> (accessed on 16 October 2020).
107. FDA. Adzenys ER Suspension, Extended Release; Oral. Medication Guide. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1cc8d0-4231-41ea-8535-4fd872129713> (accessed on 16 October 2020).
108. DAILYMED. Children's Tylenol® Cold Plus Cough Plus Sore Throat—Acetaminophen and Dextromethorphan Hydrobromide Suspension. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e83f7911-22b4-4ffc-8f49-68f6acd2ebf5> (accessed on 15 October 2020).
109. DAILYMED. Dyanavel XR—Amphetamine Suspension, Extended Release. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553> (accessed on 15 October 2020).

110. DAILYMED. Midazolam Hydrochloride Syrup. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0be63f63-6a93-4782-8f9c-d13ca5ae44bd> (accessed on 19 October 2020).
111. DAILYMED. Ciprofloxacin and Dexamethasone Suspension/Drops. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f07cf7d6-c233-884e-342d-c6c8cd2c8438> (accessed on 19 October 2020).
112. DAILYMED. Allergy Eye Drops—Ketotifen Fumarate Solution/Drops. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa9133fd-166e-4f05-9ca8-851ece692874> (accessed on 19 October 2020).
113. DAILYMED. Little Remedies Decongestant Nasal Drops—Phenylephrine Hydrochloride Liquid. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8355eed-f1a2-4b4a-b65f-c2f4b28c12d1> (accessed on 19 October 2020).
114. DAILYMED. BIO-G-TUSS PEDIATRIC DROPS—Dextromethorphan HBR, Guaifenesin, Phenylephrine HCL Solution/Drops. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42045759-eaf2-4ffb-8a68-043f661acf8a> (accessed on 19 October 2020).
115. DAILYMED. Children’s Motrin—Ibuprofen Tablet, Chewable. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b0b56d-6188-4937-b541-902022e35b24#footnote-1> (accessed on 15 October 2020).
116. DAILYMED. Acetaminophen Children’s—Acetaminophen Tablet, Chewable. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cf591dba2d591dba2> (accessed on 15 October 2020).
117. DAILYMED. Diazepam Tablet. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f226e5c1-9f6f-4bae-890d-ad4bd9eaf039> (accessed on 16 October 2020).
118. DAILYMED. Dexamethasone 1.5 MG—Dexamethasone 1.5 mg Tablet. Available online: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc75691-974e-4a67-b9d7-64dde72b5595> (accessed on 19 October 2020).
119. Van Der Vossen, A.C.; Van Der Velde, I.; Smeets, O.; Postma, D.; Eckhardt, M.; Vermes, A.; Koch, B.C.P.; Vulto, A.; Hanff, L. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug. *Eur. J. Pharm. Sci.* **2017**, *100*, 205–210. [CrossRef] [PubMed]
120. Van Der Vossen, A.; Van Der Velde, I.; Smeets, O.; Postma, D.; Vermes, A.; Koch, B.; Vulto, A.; Hanff, L. Design and stability study of an oral solution of amlodipine besylate for pediatric patients. *Eur. J. Pharm. Sci.* **2016**, *92*, 220–223. [CrossRef] [PubMed]
121. Gobetti, C.; Balsan, M.E.; Ayres, M.V.; De Almeida, S.H.O.; Simon, E.D.S.; Wingert, N.R.; Oppe, T.P.; Garcia, C.V. Development and Stability Control of Pediatric Oral Tizanidine Hydrochloride Formulations for Hospital Use. *AAPS PharmSciTech* **2020**, *21*, 1–11. [CrossRef]
122. De Goede, A.; Boedhram, R.; Eckhardt, M.; Hanff, L.; Koch, B.; Vermaat, C.; Vermes, A. Development and validation of a paediatric oral formulation of clonidine hydrochloride. *Int. J. Pharm.* **2012**, *433*, 119–120. [CrossRef] [PubMed]
123. Merino-Bohórquez, V.; Delgado-Valverde, M.; García-Palomo, M.; Dávila-Pousa, M.; Cañete, C.; Villaronga, M.; Rodríguez-Marrodán, B.; López-Rojas, R.; Cameán-Fernández, M.; The Pharmaceutical Technology Working Group and Pediatric Pharmacy Working Group of the Spanish Society of Hospital Pharmacy (SEFH). Physicochemical and microbiological stability of two new oral liquid formulations of clonidine hydrochloride for pediatric patients. *Pharm. Dev. Technol.* **2018**, *24*, 465–478. [CrossRef]
124. Lopalco, A.; Curci, A.; Lopedota, A.; Cutrignelli, A.; Laquintana, V.; Franco, M.; Denora, N. Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate. *Eur. J. Pharm. Sci.* **2019**, *127*, 339–350. [CrossRef]
125. Provenza, N.; Calpena, A.; Mallandrich, M.; Sanchez, A.; Egea, M.; Clares, B. Permeation studies through porcine small intestine of furosemide solutions for personalised paediatric administration. *Int. J. Pharm.* **2014**, *475*, 208–213. [CrossRef]
126. Kini, R.S.; Bhilegaonkar, P.S. Pharmaceutical Formulation Comprising Paracetamol Especially for Pediatrics. IN Patent 201,721,007,863, 7 March 2017.
127. Santoveña, A.; Sánchez-Negrín, E.; Charola, L.; Llabrés, M.; Farina, J.B. Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration. *Int. J. Pharm.* **2014**, *477*, 32–38. [CrossRef]
128. Santoveña, A.; Hernández-Paiz, Z.; Fariña, J. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. *Int. J. Pharm.* **2012**, *423*, 360–364. [CrossRef]
129. Alayoubi, A.; Daihom, B.; Adhikari, H.; Mishra, S.R.; Helms, R.; Almoazen, H. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics. *Drug Dev. Ind. Pharm.* **2016**, *42*, 1579–1589. [CrossRef] [PubMed]
130. Goode, G.A.; Wagh, S.J.; Irby, D.J.; Ma, D.; Jacobs, R.F.; Kearns, G.L.; Almoazen, H. Bioavailability testing of a newly developed clindamycin oral suspension in a pediatric porcine model. *Pharm. Dev. Technol.* **2019**, *24*, 1038–1043. [CrossRef] [PubMed]
131. Suthar, A.M.; Patel, M.M. Suspension of Isoniazid Formulated Using Cationic Resin for Pediatric Use. *Int. J. Curr. Pharm. Res.* **2014**, *6*, 6–10. Available online: <https://pdfs.semanticscholar.org/8c82/227ce826c2a063af50d4e90051a52ceb5285.pdf> (accessed on 2 December 2020).
132. Bhuvva, F.; Patel, L. Pediatric Nasal Spray Solution: Factorial Design Development and Evaluation. *J. Drug Deliv. Ther.* **2018**, *8*, 355–365. [CrossRef]